An Organ System-Based Synopsis of *Pseudomonas aeruginosa* Virulence

Charles D. Morin*a, Eric Dézielb, Jeff Gauthierc, Roger C. Levesqued, and Gee W. Laua

aCentre Armand-Frappier Santé Biotechnologique, Institut National De La Recherche Scientifique (INRS), Laval, Quebec, Canada; bDépartement De Microbiologie-infectiologie Et Immunologie, Institut De Biologie Intégrative Et Des Systèmes (IBIS), Université Laval, Québec City, Quebec, Canada; cDepartment of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, IL, US

**ABSTRACT**

Driven in part by its metabolic versatility, high intrinsic antibiotic resistance, and a large repertoire of virulence factors, *Pseudomonas aeruginosa* is expertly adapted to thrive in a wide variety of environments, and in the process, making it a notorious opportunistic pathogen. Apart from the extensively studied chronic infection in the lungs of people with cystic fibrosis (CF), *P. aeruginosa* also causes multiple serious infections encompassing essentially all organs of the human body, among others, lung infection in patients with chronic obstructive pulmonary disease, primary ciliary dyskinesia and ventilator-associated pneumonia; bacteremia and sepsis; soft tissue infection in burns; open wounds and postsurgery patients; urinary tract infection; diabetic foot ulcers; chronic suppurative otitis media and otitis externa; and keratitis associated with extended contact lens use. Although well characterized in the context of CF, pathogenic processes mediated by various *P. aeruginosa* virulence factors in other organ systems remain poorly understood. In this review, we use an organ system-based approach to provide a synopsis of disease mechanisms exerted by *P. aeruginosa* virulence determinants that contribute to its success as a versatile pathogen.

**INTRODUCTION**

*Pseudomonas aeruginosa* is a ubiquitous Gram-negative bacterium found in soil and surfaces of aqueous environments. Because of its metabolic versatility and high intrinsic resistance to antimicrobials, *P. aeruginosa* efficiently adapts and thrives in a wide variety of natural and artificial settings, including in-hospital facilities and patient devices. Although rarely infecting healthy individuals, *P. aeruginosa* is a leading and notorious opportunistic pathogen [1,2], especially in immunocompromised patients with defective immune defenses, including chronic neutropenia and defects of neutrophil function, cancers, human immunodeficiency (HIV) acquired immunodeficiency syndrome (AIDS), and diabetes mellitus. *P. aeruginosa* is best known to chronically colonize and infect the lungs of people with cystic fibrosis (CF) and advanced stages of chronic obstructive pulmonary disease (COPD) [3,4]. Also, *P. aeruginosa* is responsible for approximately 4% total cases of hospital-acquired bloodstream infections, and was the third leading cause among Gram-negative pathogens [5]. Nosocomial pneumonia, especially the ventilator-associated pneumonia (VAP) is a major cause of morbidity and mortality in critically ill patients, and the isolation of *P. aeruginosa* is associated with worse clinical outcomes [6,7]. *P. aeruginosa* is also known to cause a wide variety of other infections, encompassing all organs of the human body, including soft tissue infection in burns, open wounds and postsurgery; urinary tract infection associated with the use of urinary catheter; foot infection in diabetics and individuals with impaired microvascular circulation; ear infection, especially otitis externa and chronic suppurative otitis media associated with tissue injury and water blockage; and keratitis associated with extended contact lens wear and contaminated contact lens [8]. Other rarer but serious infections include endocarditis occurring in patients with or without injection drug use [9,10]; and meningitis associated with penetrating trauma to the head, placement of a CNS shunt (such as a ventriculoperitoneal (VP) shunt), or post-neurosurgical procedures [10,11]. Poor antibiotic stewardship in the past few decades has led to emergence and spread of multidrug-resistant strains. Effective treatment options are increasingly scarce; consequently, *P. aeruginosa* infections are
associated with high morbidity and mortality. Not surprisingly, carbapenem-resistant *P. aeruginosa* is classified as a serious threat by the Centers for Disease Control and Prevention of the United State (US CDC, https://www.cdc.gov/drugresistance/biggest-threats.html), and is on the World Health Organization (WHO) Priority list of pathogens for research and development of new antibiotics (https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf). In this review, we use an organ system-based approach to provide a brief overview of pathogenic mechanisms exerted by *P. aeruginosa* virulence factors that contribute to its success as a versatile pathogen (Figure 1).

**VIRULENCE FACTORS**

This section presents a brief summary of the main virulence factors of *P. aeruginosa* and their mechanisms of action. Detailed function of these virulence factors specific to individual organ systems are presented in their respective sections.

**Biofilm formation**

Establishment of a microbial biofilm relies on the formation of a matrix composed of extracellular polymeric substances that embeds the bacteria together into a robust colony [*P. aeruginosa* biofilm formation has been reviewed in details here [12]]. The production of this matrix allows for long-term persistence of *P. aeruginosa* on biotic and abiotic surfaces by shielding the population from antimicrobial agents and adverse conditions. Three exopolysaccharides – Pel, PsI and alginate – along with extracellular DNA and proteins constitute the bulk of the exopolymeric substances forming the matrix. These bacterial biofilm communities are typically refractory to antibiotic therapy and

![Figure 1. Virulence factors of *Pseudomonas aeruginosa* important for infection in human organs.](image-url)
resistant to host immunity, and are therefore, difficult to treat.

**Exoproducts and secretion systems**

*P. aeruginosa* secretes a multitude of toxic metabolites, often through protein complexes called secretion systems (reviewed in the context of *P. aeruginosa* [13]; all known families of secretion systems [14]). The Type 1 secretion system (T1SS) exports the alkaline protease AprA. The Type 2 secretion system (T2SS) is responsible for the secretion of multiple virulence factors, notably: exotoxin A (ToxA), proteases LasA and LasB, and the hemolytic phospholipase C (PlcH) [13]. The Type 3 secretion system (T3SS) is a needlelike nanomachine that delivers toxic effectors – ExoS, ExoT, ExoU and ExoY – into the target host cell (reviewed in [15]). Additionally, a subgroup of T3SS-deficient *P. aeruginosa* clinical isolates cause hemorrhagic pneumonia by secreting the exolysin ExLA through the Type 5 secretion system (T5SS) [16]. The Type 6 secretion system (T6SS) apparatus is mostly involved in secretion of effectors for interbacterial killing, although some T6SS effectors target eukaryotic hosts [17].

Pyocyanin is one of the phenazines secreted by *P. aeruginosa* that imparts a blue color to many abscesses and burn wounds infected by the pathogen. Among the phenazines, pyocyanin is best studied, and is considered most toxic because of its redox-active and zwitterionic properties. Pyocyanin easily traverses the cell membrane and causes oxidative stress by generating reactive oxygen and nitrogen species (ROS and RNS), which allow *P. aeruginosa* to kill competitor microbes inhabiting the same niche, as well as damaging host cells or modulating their immune signaling [18].

*P. aeruginosa* also produces rhamnolipids (RLs), a class of amphipathic glycolipids with surface-active properties [19]. Despite the immense interest toward RLs as an ecological alternative to synthetic surfactants [20], their role in *P. aeruginosa* virulence has been proportionally underappreciated.

**Quorum sensing**

“Quorum sensing” (QS) is the archetypal intercellular signaling system used by many bacteria to regulate their gene expression co-ordinately and synergistically as a group [21]. N-acyl-L-homoserine lactones (AHLs) are the signals mediating the well-characterized QS system used by many Gram-negative bacteria [21,22]. The complex QS regulatory pathway in *P. aeruginosa* controls the expression of multiple virulence factors (recently reviewed in [23,24]). In this species, two separate transcriptional regulator/autoinducer synthase pairs, LasR/LasI and RhlR/RhlI, modulate the transcription of target genes in response to their respective cognate AHLLs, oxo-C12-HSL and C4-HSL [25]. *P. aeruginosa* also produces QS signals distinct from AHLLs, the 4-hydroxy-2-alkylquinolines (HAQs) [26], such as 3,4-dihydroxy-2-heptlyquinoline, the *Pseudomonas* Quinolone Signal (PQS) [27]. The transcriptional activator MvfR (aka PqsR) controls the biosynthesis of HAQs [26] by the pqsABCDE operon [26,28,29]. The enzyme PqsH [28,30] is also required for synthesis of PQS, the main autoinducer of MvfR [29,31]. All three QS systems play a vital role in *P. aeruginosa* pathogenesis [32–34], upregulating (directly or indirectly) the transcription of over 300 genes [35–37], many encoding virulence functions [32,38], including the elastase LasB [39], hydrogen cyanide, phenazines such as pyocyanin [40], RLs [41], biofilm development [42] and two of the T6SSs [43,44].

**Iron acquisition systems**

Since iron is a limiting microelement in the environment because of its low solubility in the ferric form (Fe$^{3+}$), *P. aeruginosa* evolved multiple molecular mechanisms to scavenge this essential but scarce resource (reviewed in [45]). Two iron-binding siderophores, pyoverdine and pyochelin, are secreted. These siderophores have high and low affinities for ferric iron, respectively, and once iron-bound they can be imported back into the cell. When ferrous iron (Fe$^{2+}$) is available, for instance, under anaerobic conditions or following reduction by phenazines, *P. aeruginosa* utilizes its Fe$^{2+}$ uptake system FeoABC. *P. aeruginosa* also possesses three heme import systems to acquire iron from the host hemoproteins, including the Phu (*Pseudomonas* heme uptake) and the Has (heme assimilation system), and the recently discovered Hxu system [46].

**Cellular appendages and adhesins**

*P. aeruginosa* possesses various means of motility and attachment, namely a polar flagellum (reviewed in [47]), multiple types of type IV pili (T4P: type IVa, IVb pili, tight adherence pili; all reviewed in [48]), chaperone-usher-pathway (cup) fimbriae (reviewed in [49]), and other adhesins such as the two carbohydrate-specific lectins: PA-IL (also named LecA) and PA-III (also named LecB) (reviewed in [50]). The lipopolysaccharide (LPS) is a constituent of the external layer of the outer membrane comprised of lipophilic anchor lipid A, an inner oligosaccharide core and an outer oligosaccharide
chain, the O-antigen [51]. The presence of these appendages on the bacterial cell surface means that they are recognized by the immune system of the host.

**LUNG INFECTION**

The human respiratory system is divided into the upper and lower tracts. The upper tract is composed of nasal cavity, pharynx and larynx whereas the lower tract includes the trachea, primary, secondary and tertiary bronchi, bronchioles and ≥ 700 millions alveoli with a mesh-like network of tiny capillaries and venules where gas exchanges occur. Apart from gas exchanges, the respiratory system as a whole is also involved in sensing the environment, secretion, regeneration, preventing infections, processing toxins and removing debris. Airway secretory cells produce mucins and antimicrobial peptides and metabolize toxins, whereas ciliated cells use their cilia to propel debris out of the lung [52]. A recent single-cell RNA sequencing analysis of approximately 75,000 cells spanning the entire lung compartments and circulating blood has further defined the gene expression profiles and anatomical locations of 58 cell populations within the human lung, including 14 uncharacterized cell types. This molecular atlas provides novel insights into the functions, regulation and interactions of the known and new cell types, and will likely engender major advances in our understanding of pulmonary biology and the interactions between lung and *P. aeruginosa* and other respiratory pathogens [53–55].

The human lung presents a challenging immunological dilemma for the host. While simultaneously facilitating vital gas exchanges, it is constantly bombarded by chemicals, pollutants and microbes inhaled from the environment [54]. The epithelial surface of healthy airways is covered by the airway surface liquid (ASL), which is comprised, among others, of mucins, antimicrobial peptides and proteins, innate immune cells, and signaling molecules. The bilayer ASL contains the periciliary layer sandwiched between the top mucus gel layer and the bottom airway epithelium, forming the so-called “gel-on-brush” structure [55]. Hydrogel within the periciliary layer provides space for ciliary beating and supports mucociliary clearance. The predominant mucins MUC5AC and MUC5B provide viscosity and gel-forming properties to mucus, which traps inhaled pathogens and irritants, keeps moisture in the airway epithelium [56], and helps to maintain the periciliary layer and mucociliary clearance. Both MUC5AC [57] and MUC5B [58] are critical for innate immune defense of the airways against microbial infection.

However, excessive mucus and failure in clearance by the mucociliary escalator will clog the airways, which will then reduce and prevent air flow into the alveolar space. This is a common pathological condition found in multiple lung diseases such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), asthma, primary ciliary dyskinesia, chronic bronchitis and VAP. Excessive mucus creates a niche for microbial colonization, which will exacerbate vicious cycles of proinflammatory response, lung damage, and morbidity and mortality [59–62].

Two of the best-studied chronic lung diseases where microbial infections play a critical role in disease pathogenesis are CF and COPD. CF is a fatal genetic disorder affecting approximately 70,000 individuals worldwide. Although most commonly found in the Caucasian population, with 1 in 2,000 to 3,500 cases, CF is also found among other ethnic populations, at 1 in 16,000 to 17,000 among Africans, and at 1 in 30,000 among Asians. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a chloride (Cl−) channel. The loss of CFTR function reduces Cl− secretion, causing an increased transepithelial absorption of sodium and water. This results in thickening of the mucus in the airways, which slows down and disables the mucociliary escalator function, creating a suitable niche for microorganisms to thrive [4,63,64]. The major clinical problem for CF patients is progressive loss of pulmonary function caused by chronic lung infection with *P. aeruginosa*, which causes morbidity and mortality, with an average life expectancy in the 40s. Repeated bouts of inflammation triggered by the bacterium progressively damage the lung. Although antibiotics can decrease the frequency and duration of acute infectious exacerbations, this opportunistic pathogen establishes permanent residence and is never completely eradicated from lungs. COPD is a leading cause of morbidity and mortality worldwide, affecting 329 million people and cause over 3 million deaths annually [65,66]. The odds of developing COPD are increased by cigarette smoking, exposure to air pollutants, biomass smoke (e.g., indoor wood burning), and toxic desert dusts inhaled by soldiers in the Middle East [65–69]. Long-term exposure to these irritants exacerbates the inflammatory response, narrows the small airways, and causes emphysema. The most common symptoms of COPD are excessive mucus and sputum, shortness of breath, chest tightness and wheezing. The majority of cases of acute exacerbation in COPD are caused by microbial infections [70,71],
among which, *P. aeruginosa* is a common cause of severe exacerbations, especially in advanced stages of COPD [3,72,73].

Because *P. aeruginosa* is metabolically versatile, possesses high intrinsic antibiotic resistance, and expresses a large repertoire of virulence factors, it is proficiently adapted to thrive in a wide variety of environments, and in the process, making it a notorious opportunistic pathogen in the complex proinflammatory milieu within chronically diseased lungs such as CF and COPD. Most of our understanding of *P. aeruginosa* pathogenesis is derived from the context of CF. Various virulence factors that drive lung colonization and infection are briefly summarized below.

**EXOPOLYSACCHARIDES AND BIOFILMS**

**Biofilms**

Biofilm formation plays key roles in the persistence of *P. aeruginosa* in chronically diseased lungs, especially in CF (reviewed in [74]). Long-term growth in the CF lung environment gives rise to different phenotypic variants of *P. aeruginosa*, two of which exhibit enhanced biofilm-producing phenotypes: mucoid variants and small colony variants (SCVs) [75,76].

**Exopolysaccharides alginate, Pel and Psl**

Mucoidy results from the overproduction of alginate, due to a mutation in the gene coding for the anti-sigma factor MucA [75]. A long-term study of 56 CF patients revealed a median time of about 11 years for the transition of non-mucoid *P. aeruginosa* (normally acquired in the first years of life) to a mucoid variant, a transition followed with worsening symptoms [77]. Production of alginate has been linked to increased resistance to host-produced antimicrobial peptides, phagocytosis by leukocytes and antibiotics [78–81]. Despite their apparent benefits, mucoid isolates are often present as mixed populations with their non-mucoid counterpart, the latter often being the product of phenotypic reversion due to suppressor mutations in algT [82,83]. Such mixed population might be at an advantage, as Malhotra et al. (2018) demonstrated that a mixed population of mucoid and non-mucoid variants is more resistant to both antimicrobial peptides (conferred by mucoid members of the population) and H$_2$O$_2$ (resistance granted by the non-mucoid subpopulation) [81]. A recent study assessing the distribution of mucoid and non-mucoid isolates from bronchoalveolar lavages of specific lobar regions of the lungs confirmed that mucoid variants do not preferentially localize to certain lobes, and that their presence is marked by elevated levels of proinflammatory cytokines in colonized regions [82]. Alginate might also play an important role in the context of mixed bacterial infections in the CF lungs. Alginate leads to reduced killing of *Staphylococcus aureus* by *P. aeruginosa* in an in vitro co-culture [84]. The same study showed that this protective effect can be achieved simply by adding exogenous alginate to a co-culture with an alginate biosynthesis deficient mutant of *P. aeruginosa*. Exogenous alginate increased the persistence of *Burkholderia cenocepacia*, *B. multivorans*, *Haemophilus influenzae*, but not *Stenotrophomonas maltophilia* and *B. cепacia*, in the lungs of a CFTR knockout mouse [85]. These six other bacterial pathogens are also prevalent in the CF lungs [86].

Like their name suggests, SCVs appear as smaller colonies when grown on an agar surface (reviewed in [87]). The emergence of a subpopulation of SCVs is a frequently observed feature of *P. aeruginosa* isolates from CF lungs biofilms [76,88]. The first characterization of SCVs from CF patients highlighted a two to eight-fold increase in resistance to antibiotics [89]. This same study also indicated that SCVs are found more predominantly in patients undergoing aerosolized antibiotics therapy in contrast to those with intravenous therapy. These results suggest that antibiotic aerosolization leads to the emergence of drug tolerance in SCVs. The presence of SCV is also correlated with severe impairment of lung function [89]. Like the mucoid variants, SCVs promote persistence in the CF lungs as they possess higher resistance to neutrophil antimicrobials such as H$_2$O$_2$ and antimicrobial peptides and cause more inflammation [90].

The importance of biofilms in pulmonary infections is also highlighted in a study where transcriptomics were used to compare transcript levels between multiple CF sputum samples and lab-grown clinical isolates were compared [91]. Among the key differences between both groups of samples, there was a marked increase in the transcript levels of Pel, Psl and alginate biosynthesis pathways in CF sputum samples compared to lab-grown isolates [91]. Both Pel and Psl, but not extracellular DNA, were found to play an important role in the in vitro formation of biofilm by mucoid *P. aeruginosa*; both exopolysaccharides also contributed to the resistance of the same mucoid strain against host defense in a mouse model of acute pneumonia [92].

*P. aeruginosa* biofilms also play a role in the pathogenesis of VAP (reviewed in [93]). Biofilms will form on the endotracheal tube upon intubation of a patient, providing a direct access to the lower respiratory tract.
[94]. A study compared the in vitro biofilm formation capabilities of clinical isolates from mechanically ventilated patients and CF patients, and found that all isolates from intubated patients produced more biofilm in a 96-well plate assay than both CF isolates and the reference strain PAO1 [95]. Although not fully understood, these VAP strains are likely better adapted to form biofilms on rough and porous plastic surfaces of microtiter plates and medical devices. Additionally, these authors also found that strains which produce more biofilms are positively correlated to heightened antibiotic resistance, particularly to β-lactam antibiotics, suggesting a selection pressure to hyper biofilms producing phenotype.

QUORUM SENSING

QS mutants of P. aeruginosa are attenuated in their ability to cause mortality in various hosts [96-101]. P. aeruginosa mutants lacking QS regulatory genes cause less lung pathology in mouse and rat models, suggesting that cell-to-cell signaling plays a key role in virulence [97,98,101]. For instance, a lasR- mutant was virtually avirulent in a neonatal mouse model of pulmonary infection compared to pneumonia caused by the parental wild type strain PAO1 [102]. In addition, sputum samples and lung exudates from CF patients chronically infected with P. aeruginosa contain significant amounts of AHLs and PQS, indicating that all three QS systems are functioning during human infection [103,104].

It is noteworthy that P. aeruginosa isolates from chronically infected CF patient lungs, but not from acute infections, frequently contain lasR mutations. [105-107] Loss of LasR function occurs over the years in these chronically colonized individuals, indicating strong selective pressure against LasR activity [107-109]; a marker of poor prognosis, these mutants are associated with progression of the CF disease [106]. Interestingly, Feltner et al. (2016) have shown that some LasR-deficient variants isolated from CF lungs have maintained a QS-dependent virulence gene expression, through RhlR activity [110]. In these isolates, the authors noted that “there is apparently no correlation between the absence of a functional LasR and a variety of quorum-regulated phenotypes”.

Multiple studies have demonstrated that AHLs, especially oxo-C12-HSL, are able to modulate host immune functions, with both detrimental or beneficial effects [reviewed here [111,112]]. Oxo-C12-HSL induces the chemotaxis of neutrophils, and increases their phagocytic capacity, which could be due to modulation of (CD)11b/CD18 integrins and CD16 and CD64 immunoglobulin receptors [113]. Similarly, oxo-C12-HSL stimulates phagocytic activity of human macrophages by inducing the p38 MAPK, which causes positive changes in cell volume, morphology, and water channel AQP9 that promotes phagocytosis [114]. In contrast, oxo-C12-HSL, but not C4-HSL, induces apoptosis in phagocytic cells [115], interferes with proper functioning of mitochondria [116], and alters the expression and secretion of multiple pro- and anti-inflammatory cytokines and chemokines [117,118]. However, these results need to be interpreted with caution because the vast majority of host modulation studies were performed in vitro using oxo-C12-HSL in concentrations between 300 and 600 μM, often in different immortalized cell lines. In contrast, only low μM concentrations of C4-HSL and low nM concentrations of C12-HSL have been detected in CF lungs [103,104,119,120]. Nevertheless, it is possible that during biofilm-mediated infection, locally-enhanced concentrations of QS molecules and virulence factors could modulate host immune functions.

CELL APPENDAGES AND ADHESINS

Flagellum

As presented above, P. aeruginosa uses various mechanisms for attachment and motility. A P. aeruginosa mutant that lacks its flagellar fiber is more sensitive to the membrane permeabilizing activity of the pulmonary surfactant protein A. This protective effect was linked in part to a lack of O-antigen in the outer membrane of flagellum-null mutants and reduced expression of secreted proteases which would degrade the surfactant protein A [121,122]. In a mouse model of acute pneumonia, a non-lethal dose of P. aeruginosa expressing its flagellin fiber was cleared more rapidly by the host, while challenge with a lethal dose (equivalent to the LD50) led to more rapid killing of mice, compared to mutants lacking the flagellum [123]. The flagellin acts as an adhesin capable of binding to the mucin Muc1 when expressed in the CHO cell line [124].

Type IV pili

P. aeruginosa mutants lacking either pilT and pilU, both encoding proteins responsible for the retraction of the T4P, still express surface T4P but show reduced cytotoxicity against lung pneumocytes, lower cell adhesion and attenuated virulence in a mouse model of acute pneumonia [125]. In the same study, a pilin (pilA)-null mutant showed an even more pronounced reduction in
virulence [125]. Similar to flagellin, the presence of T4P at the surface of the cell also confers a protective effect against the opsonizing activity of the surfactant protein A, which implicates a O-glycosylation present in group I alleles of the pilin subunit [126]. A study reported an increased prevalence of group I pilin alleles in isolates from CF patients, compared to non-CF clinical isolates [127].

Both the flagellum and T4P are known to play a role in the formation of biofilm in vitro, as mutants of each appendage are impaired at the step of initial attachment and microcolony formation, respectively [128]. These appendages are both important for the binding to lung epithelial cells through different mechanisms: T4P will bind N-glycans at the apical surface of polarized cells while the flagellum will bind to heparan sulfate present at the basolateral side of the cells [129]. Both events will lead to the internalization of P. aeruginosa into the cells [129].

On the other hand, using Tn-seq with a transposon mutant library of strain PA14 in an acute pneumonia mice model, Lorenz et al. (2019) found that the flagellum and T4P were not required to cause infections [130]. In fact, mutants with transposon insertions in the pili and flagellar biogenesis operons (pil, flg and fli operons) were enriched (positively selected) in this infection model. Since both pili and flagellar fiber proteins can be recognized by the immune system of the host, the authors suggested that loss of those components might help with immune evasion to prevent bacterial clearance [130,131]. Mucoid variants from CF lungs are non-motile: the lack of functional MucA in these variants will lead to a constant activation of the alternative sigma factor AlgT, which will in turn activate a repressor of flagellar biosynthesis (AmrZ) [75,132]. The flagellum and T4P are still useful during the initial process of infection; however, it is likely that some selective pressure will lead to members of the total bacterial population to lose this trait over time. Part of the selection pressure is mediated through the interaction between the flagellum and NLRC4 inflammasome. Induction of NLRC4 by the flagellum, primarily in alveolar macrophages, impaired P. aeruginosa clearance and increased apoptosis/pyroptosis and mortality in a murine model of acute pneumonia [133].

**Lectins**

LecA and LecB produced by P. aeruginosa have multiple roles in the outcome of lung infections. Single mutants of both lectins are impaired in their ability to adhere to a human lung epithelial cell line, have reduced cytotoxicity and cause reduced permeabilization of the alveolar capillary barrier in mice (without affecting mortality) [134]. The same study showed that carbohydrate lectin inhibitor will counter the effect of their respective lectin by titrating their binding sites. LecA binds to the glycosphingolipids Gs3, triggering phosphorylation of the adaptor protein CrkII by activating the non-receptor tyrosine kinase Abl inside the host’s cell that initiates the internalization of P. aeruginosa [135]. Mutation in either lecA or lecB genes will result in impaired biofilm formation by P. aeruginosa [136,137]. A recent study reported that LecB binds to the side chain of Psl and help stabilize the biofilm matrix [138]. LecB is also implicated in the reduction of tissue healing [139,140].

**EXOPRODUCTS AND SECRETION SYSTEMS**

**Secretion systems**

As discussed above, P. aeruginosa expresses five different secretion systems that play a role in virulence (reviewed in [13]). The alkaline protease AprA exported by TSS1 cleaves the γ-subunit of the epithelial sodium channel ENaC in vitro on both CF and non-CF lung epithelial cells, leading to changes in the sodium balance near the cells. AprA also cleaves other proteins including transferrin, complements and cytokines, hence facilitating iron uptake and immune evasion [141,142].

The T2SS secretes ToxA, LasA, LasB, and PlcH [13]. The elastase LasB degrades a number of components in both the innate and adaptive immune systems, for instance an absence of LasB secretion impairs the ability of P. aeruginosa to degrade pulmonary surfactant protein-A, both in vitro and in mouse lungs [143]. By assessing the virulence of T2SS-null mutant deficient in the Xcp secretin, a study highlighted the importance of the effectors secreted by this system: lack of T2SS increased the survival of mice in the context of lung infection [144]. The same study reported that T3SS is responsible for the early killing of mice, while T2SS has a more pronounced impact at later stages of the infection process. This is in agreement with the fact that Xcp and its effectors are positively regulated by the QS [144].

Of the four T3SS effectors injected into the host cells, ExoU contributes the most to the virulence in a mouse model of lung infection, followed by ExoS [145], ExoS, ExoT and ExoY are all implicated in the systemic dissemination of P. aeruginosa from the lung during acute pneumonia [146]. The main cell types injected with ExoU were macrophages during early pneumonia, followed by neutrophils in the latter time.
points once the immune systems starts building its response to the infection [147]. In a mouse model of acute pneumonia, the transcription of exoU was increased as early as 3 hours post-infection, and a delayed expression of this exoenzyme resulted in a significantly reduced bacterial burden [148]. Both ExoU and ExoS are mutually exclusive in the arsenal of P. aeruginosa, with the presence of exoU in clinical isolates being lower [149]. None of 24 nonclonal isolates from adult CF patients harbor the exoU gene [150]. The contribution of ExoY to P. aeruginosa pathogenesis is not as obvious [151]. Loss of exoY or its effect alone have little impact on the outcome; however, its overexpression by a high-copy-number plasmid leads to increased and sustained inflammation in a mouse model of lung infection [151]. ExoY is a nucleotidyl cyclase that produces cyclic nucleotides, mainly cUMP, which in turn causes a dysregulation of microtubules, reduction of tissue healing and release of toxic phosphorylated tau proteins [151–153]. Interestingly, the T3SS nanomachine in itself also bear some importance in the pathogenesis of P. aeruginosa independent of its known secreted effectors since a mutant lacking the translocator protein PopB was more avirulent than mutants lacking all T3SS effectors in a mouse model of acute pneumonia [154].

The hemolysin ExlA secreted by the T5SS perforates mammalian cell membranes and disrupts the ion balance of the host cells, leading to cell death [155]. ExlA also breaks down the alveolar-capillary barrier and facilitates invasive dissemination of P. aeruginosa to other organs [156].

Although most effectors secreted by the T6SS are devoted to interbacterial killing and competition, some of them also modulate host response [17]. Two such T6SS effectors are the phospholipase D PldA and PldB (also known as Tle5 and Tle5B) secreted by the third T6SS complex (H3-T6SS), both can cause lysis of other prokaryotes and trigger pathways that will facilitate P. aeruginosa entry into the mammalian host cell [157,158]. Phospholipase D is also associated with persistency since pldA-null mutants were severely outcompeted by their wild-type parental strain in a rat chronic lung infection model [159].

**Rhamnolipids**

For decades, RLs were only known as the heat-stable extracellular hemolysin of P. aeruginosa [160–164]. Then Kowatzki et al. found that sputum samples obtained from people with CF colonized with P. aeruginosa contained RLs [165]. This was followed by measurement of even higher levels in secretions of a lung removed from a CF patient [166], suggesting that higher concentrations are present in the lower respiratory tract. Eventually, a correlation was reported between elevated levels of RLs and worsened patient’s clinical status [166]. This is not restricted to CF, though, as another study found that patients persistently colonized by P. aeruginosa isolates producing high levels of RLs were at increased risk of developing a VAP [167]. Significantly, the importance of RLs for the establishment of an actual infection was demonstrated: a RL-negative mutant was more rapidly cleared from a pulmonary infection mice model compared to the wild type strain [168].

Several properties of RLs makes them versatile virulence factors. RLs inhibit ciliary function of the bronchial epithelium. They alter respiratory epithelial ion transport through reduced sodium absorption and unidirectional chloride fluxes across human bronchial epithelium [164], they interfere with the normal tracheal ciliary function of rabbit tracheal epithelium [169] and slow down the ciliary beat frequency of cultured human airway epithelium [166,170]. RLs also stimulate the release of mucus glycoconjugates from feline trachea and human bronchial mucosa [171,172].

RLs are involved in the early disruption of the integrity of the polarized bronchial epithelia. Normal function of tight junction protein complexes is crucial for lung defense against infections. RLs promote infiltration of P. aeruginosa by altering tight junctions in the respiratory epithelium [173–175]. For instance, RLs disrupt transcellular ion transport, as observed by a decrease in amiloride-sensitive short-circuit current across sheep tracheal epithelium [173]. P. aeruginosa required the production of RLs to invade respiratory epithelia reconstituted with primary human respiratory cells [175]. Using an air-liquid model of human airway epithelia, Halldorsson et al. (2010) found that RLs reduced transepithelial electrical resistance and tight junction rearrangement [176].

RLs have been proposed to solubilize the phospholipids composing the lung surfactant, making them more easily cleavable by phospholipase C (PlcH). The resulting loss of lung surfactant may be responsible for the atelectasis associated with acute and chronic P. aeruginosa lung infections. RLs may also intercalate into, and thus perturb, the phosphatidylcholine bilayers, affecting the alveolar surface layer and thus the function of the membrane [177,178].

Not surprisingly, considering they are surfactants, RLs act directly on immune cells. The production of RLs appears important for the initial stage of infection to protect bacteria against the cellular components of the immune system. RLs injected intratracheally into
rat lungs inhibited the response of alveolar macrophages [179], and, at higher concentrations, they were cytolytic to human monocyte-derived macrophages [180]. *P. aeruginosa* responds to the presence of polymorphonuclear leukocytes (PMNs), major immune determinants of the CF lungs, by upregulating the production of several virulence factors, including RLs, acting to inactivate cells of the host defense. RLs induce the lysis of PMNs while [168,181,182], at subtoxic levels, they stimulate both chemotaxis and chemokinesis of PMNs [182]. RLs also induce histamine release from mast cells [183], stimulate the production of the inflammatory mediators serotonin and 12-hydroxyeicosatetraenoic acid from human platelets [184], and also stimulate the release of interleukin (IL)-8, GM-CSF, and IL-6 from nasal epithelial cells [185].

Finally, although the direct effect on *in vivo* biofilm has yet to be directly demonstrated, RLs are involved in the regulation of *in vitro* biofilm development, a key virulence function in lung infection, as discussed above. This role of RLs has been reviewed previously [186], and therefore is only briefly discussed here. RLs participate in the regulation of cell-surface hydrophobicity and in the modification of bacterial adhesive interactions [187-189]. They facilitate the initial formation of microcolonies and the differentiation of the biofilm structure [190], by mediating the detachment and dispersion of *P. aeruginosa* cells from the biofilm [187,191] and by maintaining open the channels inside the biofilm [192].

**Pyocyanin**

Pyocyanin has been recovered from CF and non-CF bronchiectatic airways at 0.1 mM concentrations [193,194]. Earlier studies have shown that pyocyanin damages ciliated epithelium, interferes with ciliary function, inhibits mucus transport [193], induces neutrophilia and bronchoconstriction in sheep airways [195,196], and decreases mucus velocity in trachea [197,198]. Additionally, the levels of pyocyanin negatively correlate with the lung function of CF patients [194]. Importantly, pyocyanin has been shown to be important for both acute and chronic lung infection [199,200]. Further studies have shown that mouse lungs chronically exposed to pyocyanin develop goblet cell metaplasia and hyperplasia, mucus hypersecretion, fibrosis, emphysema, polarization of an initially T helper cell (Th) 1 toward a Th2 response at chronic stage, with influx of neutrophils, CD4⁺ T cells and activated macrophages [200]. These phenotypes are similar to chronically-diseased airways and to foxa2⁻/⁻ mice [201]. FOXA2 is a major transcriptional regulator of airway mucus homeostasis [62]. Subsequently, it was shown that pyocyanin drives goblet cell metaplasia and hyperplasia and mucus hypersecretion by activating both IL-4/IL-13-STAT6-SPDEF and ROS-EGFR-MEK1/2-ERK1/2 signaling pathways, which converged to inhibit FOXA2 [200,202-205]. Finally, pyocyanin also inhibit FOXA2 expression by ROS/RNS-mediated posttranslational modifications [206].

**IRON ACQUISITION SYSTEMS**

Using dual-seq transcriptomics of *P. aeruginosa* infection, Damron et al. (2016) highlighted what they called a “battle for iron” [207], Transcript levels of iron acquisition systems in *P. aeruginosa* were found upregulated while the host cells increased its expression of iron sequestering proteins such as ferritin, lactoferrin, ceruloplasmin and haptoglobin [207]. *P. aeruginosa* produces two siderophores – pyoverdine and pyochelin – the former is required for growth in a medium where iron is bound to transferrin, underlining a better capacity for pyoverdine to compete with host iron carriers. The iron-starvation sigma factor PvdS is expressed by *P. aeruginosa* in infected CF lungs [208], and is required for biofilm formation [209]. PvdS also regulates the transcription of genes encoding major virulence factors such as pyoverdine, PrpL and AprA proteases [210], and ToxA [211]. In a mouse model of acute pneumonia, a *P. aeruginosa* mutant deficient in pyoverdine production was more severely attenuated and caused less mortality when compared to a mutant without pyochelin [212]. Additionally, the loss of the *tonB* gene, which encodes a protein that delivers energy to outer membrane transporters important for the uptake of iron, siderophores and other nutrients, renders the mutant bacterium completely avirulent [212,213]. Significantly, *in vivo* pyoverdine production by CF isolates of *P. aeruginosa* correlated to their virulence potential during murine lung infection [214]. However, it is important to note that a sizable portion of CF isolates has also lost their ability to produce pyoverdine, possibly through the emergence of cheats [215], or adaption toward heme acquisition [216]. Both the ferrous iron uptake system Feo and heme uptake systems Has and Phu also play a minor role in virulence, less important than pyoverdine [212]. The Hxu system has a minor role in heme acquisition when the Has and Phu
systems are fully functional, or when other sources of iron are present. However, in the absence of the Has system, *P. aeruginosa* upregulates the expression of Hxu. The contribution of the Hxu system to *P. aeruginosa* virulence remains uncharacterized [46].

**GENETIC TRANSFER, DRUG RESISTANCE AND INCREASED VIRULENCE**

The evolutionary process of natural selection, gene loss and acquisition [217,218], natural genetic transformation [219], horizontal gene transfer [220], and emergence of hypermutators during acute VAP and/or chronic CF lung infection can lead to changes in antimicrobial resistance (AMR) and virulence behavior of *P. aeruginosa* [210,221]. The *P. aeruginosa* pan-genome contains a collection of 3,010 putative and plasmids DNA genes obtained by horizontal gene transfer with 5% to 12% encoding AMR and virulence genes [222]. Diversification of the *P. aeruginosa* population in flexible genes indicated that 10,515 (40%) of the 26,420 flexible genes were found in one group of isolates; whereas 85 genes were in more than 90% of the isolates of a single group and were not found in the other groups. Flexible genes (15,905, 60%) present in multiple groups indicated an upper estimate of genes from HGT events. This would suggest that there is a link between virulence factor profiles, AMR and the population structure in *P. aeruginosa*.

Finally, although *P. aeruginosa* virulence determinants that are key to COPD chronic infections have been poorly studied, there are indications they are very similar to those involved in CF [218,219,223].

**EAR INFECTIONS**

Middle ear infections (otitis media, OM) are among the most common ear diseases affecting humans. Children, especially those under the age of two, are particularly susceptible to develop OM. Typically, OM is caused by a dysfunction of the eustachian tube connecting the middle ear to the throat. The eustachian tube equalizes the pressure between the outer ear and the middle ear. However, disruption of eustachian tube caused by a common cold, allergies and/or malformations prevents proper drainage, leading to a buildup of middle ear fluid behind the eardrum. The accumulated fluid becomes a culture media supporting the growth of bacteria and viruses that lead to acute OM. If improperly treated, OM can cause considerable morbidity and with extra- and intracranial complications, which seriously compromise the quality of life in patients. OM can be further broadly classified into acute otitis media (AOM) and chronic suppurative otitis media (CSOM). AOM is characterized by tympanic membrane swelling and/or otorrhea caused primarily by *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*, although occasionally, *P. aeruginosa* is present [224–226].

Despite appropriate therapy, AOM can progress into CSOM associated with ear drum perforation and purulent discharge. Approximately 1% of human population develop CSOM in their lifetime. CSOM is initiated by an episode of acute infection, followed by recurrent or persistent ear discharge through a perforation of the tympanic membrane. *P. aeruginosa* is the most common pathogen involved in CSOM, with a prevalence, depending on studies, between 18% and 67% [227–230]. The pathophysiology of CSOM begins with irritation and subsequent inflammation and edema of the middle ear mucosa. Ongoing inflammation eventually leads to mucosal ulceration and consequent breakdown of the epithelial lining. The cycle of inflammation, ulceration, infection, and granulation tissue formation may continue, destroying surrounding bony margins and ultimately leading to the various complications associated with CSOM, among others, including hearing loss and delayed language development in children, and serious extracranial and intracranial complications.

Additionally, *P. aeruginosa* is also the most common cause of otitis externa (OE), commonly known as “swimmer’s ear”, an infection of the external ear canal [230,231]. A large multicenter study that identified the microorganisms from 2049 ears (children and adults) with acute otitis externa (AOE) revealed that *P. aeruginosa* accounted for 71.3% of all Gram-negative organisms and for 37.7% of the total number of microbial pathogens recovered from AOE. In some rare instances, AOE can spread to surrounding tissue, including the bones of the jaw and face. This infection is known as malignant otitis externa (OEM), a virulent infection that usually affects elderly with diabetic mellitus, immunosuppressed individuals and advanced age patients. If not diagnosed and treated promptly, OEM can cause facial nerve paralysis with high mortality rate, reported to be up to 53% [232,233].

*P. aeruginosa* is also a major pathogen implicated in cholesteatoma, a destructive and expanding growth consisting of keratinizing squamous epithelium in the middle ear and/or mastoid part of the temporal bone [234]. About 40% of CSOM patients develop cholesteatoma. Bacterial-infected cholesteatomas are more aggressive than uninfected ones. Additionally, recent study suggests that the keratinizing squamous epithelia could be predisposed to infection by human papillomavirus, and DNA belonging to oncogenic
HPV16 has been detected in cholesteatoma tissues [235]. Several virulence factors of *P. aeruginosa* have been identified to play a role in the aforementioned ear infections. They are briefly summarized below.

**EXOENZYMES AND SECRETION SYSTEMS**

**Proteases**

The expression of proteases is regulated by QS [23] as well as iron availability [210]. *P. aeruginosa* proteases participate in CSOM pathogenesis. The activity of two matrix metalloproteinases, elastase and alkaline protease, along with the serine protease neutrophil elastase, were detected in the otorrhea samples from patients with OM and CSOM [236,237]. The importance of elastase and alkaline protease was confirmed by the same authors in a chinchilla model where inhibition of both proteases by the matrix metalloproteinases inhibitor GM 6001 (N-(2(R)-2(hydroxyamido carbonylmethyl)-4-methylpentanoyl)-L-tryptophane methylamide) afforded higher survival rate, less severe facial paralysis, and less vestibular toxicity than animals in other cohorts treated with the gentamicin, gentamicin plus GM 6001, or control groups, although these differences were not statistically significant [238]. Because excess neutrophil elastase causes tissue damage and alters the remodeling process in many clinical conditions including OM, most likely both *P. aeruginosa* and host proteases synergistically contribute to CSOM pathogenesis. Therefore, a protease inhibitor-based therapy targeting all these proteases will likely to be more effective [236].

**T3SS**

Although well known to be an important component of *P. aeruginosa* virulence arsenals, virtually nothing is known about the pathogenic role of T3SS during ear infection. Park et al. (2017) found that *P. aeruginosa exoU*-positive strains were more readily isolated from CSOM than from respiratory infections and bacteremia. Furthermore, these *exoU*-positive isolates were significantly more resistant to ciprofloxacin and tobramycin, which may explain the chronicity and intractability of CSOM infection [239].

**ToxA**

ToxA is a protein with ADP ribosyltransferase activity that targets host elongation factor 2. It inhibits protein biosynthesis, and in microgram quantities, could penetrate and cause irreversible damage to the inner ears of chinchillas 240 In addition, ToxA induces excessive inflammatory response dominated by polymorphonuclear leukocytes (PMNs) and monocytes/macrophages. Also, epithelial cells often showed signs of metaplasia and hyperplasia, followed by degradation through necrosis and/or apoptosis, resulting in denudation of the submucosal layer 241 Also, a wild-type *P. aeruginosa* strain (ToxA') caused significantly more semicircular canal injury and hearing loss than an isogenic ToxA- mutant 242

**Pyocyanin**

As discussed above in the lung section, pyocyanin is redox-active, and ROS and RNS generated by pyocyanin damage proteins, lipids and DNA, and alters host immune signaling [18,62,206]. A major pathophysiologic consequence of pyocyanin lies in its ability to cause excessive expression of mucin glycoproteins MUC5AC and MUC5B [62,202,205]. Importantly, pyocyanin has been detected in concentrations up to 2.714 nmole/g ear effusion of patients suffering from various ear infections, including CSOM [243]. Although MUC5B and MUC5AC play major innate immunity roles against ear infection, excessive induction of these mucins will lead to clogging of inner ear compartments, creating a niche for long term colonization and infection by microbial pathogens [244–246].

**EXOPOLYSACCHARIDES AND BIOFILMS**

**Biofilms**

Biofilm formation is important in the pathogenesis of CSOM by bacterial pathogens [247–249], although their precise pathogenic mechanisms in the middle ear are not fully understood. *P. aeruginosa* inoculated into cynomolgus monkeys which underwent perforation of the tympanic membrane formed biofilms on the middle ear mucosal surface [250]. Both the ability to produce c-di-GMP and QS were found to be important for persistence and virulence in a chinchilla model of CSOM. However, flagella were dispensable for biofilm persistence [251]. Interestingly, biofilms seem to be dispensable for cholesteatoma pathogenesis. Many *P. aeruginosa* mutants deficient in components required for normal biofilm formation (e.g., FleQ, PilA, AlgD, GalU) caused similar amounts of cholesteatomas growth and bone destruction and deposition as their parental wild-type strain [252,253].
Interestingly, the same authors have found that a T4P mutant (ΔpilA) derived from the CSOM strain OPPA8 was attenuated in cholesteatoma pathogenesis in Mongolian gerbils, although the reason for this discrepancy could be caused by strain variation [254]. Even much less is known about the role of polymicrobial biofilms in CSOM, but biofilms composed of P. aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) induced a very different gene expression profiles that are involved in immune response, inflammation, signaling, development, and defense; that are not expressed with single biofilms formed by either pathogen [255].

CELLULAR APPENDAGES AND ADHESINS

LPS

During P. aeruginosa-mediated CSOM, LPS causes mucociliary dysfunction in the middle ear by inducing nitrosylative nitric oxide (NO) and peroxynitrite (ONOO−)-mediated pathways [256]. The presence of LPS also positively correlates with several cytokines, including IL1-β, IL-8, TNF-α and RANTES in middle ear effusion aspirate from patients, suggesting that the endotoxin-induced local production of these cytokines plays a role CSOM pathogenesis [257,258]. The involvement of LPS is confirmed in the C3H/HeJ mice that harbor a single amino acid substitution in TLR4, making them insensitive to endotoxin and spontaneously develop CSOM caused by Gram-negative bacteria [259,260]. Humans with polymorphisms and reduced expression of TLRs are more susceptible to CSOM [260,261]. Finally, LPS has been implicated in the bone resorption in mouse model of CSOM and cholesteatomas [262].

OprF

The outer membrane protein OprF of P. aeruginosa activates the host PKC pathway by phosphorylation of PKC-alpha, leading to the invasion of human middle ear epithelial cells. Induction of PKC can activate the expression of proinflammatory cytokines such as TNF-α and IL-1β that can contribute to chronic inflammation [263].

OCULAR INFECTIONS

The healthy cornea of both eyes is constantly exposed to environmental pollutants, allergens and microbial pathogens, yet maintains immunologically quiescent, thus minimizing excessive damaging proinflammatory responses. However, how the cornea resists microbial infection is not fully understood. The healthy and intact mouse eyes could resist ~10⁹ bacterial cells of either P. aeruginosa or S. aureus, two most important corneal pathogens, with very few bacteria adhering to the surface and none penetrating the cornea [264,265]. Similar phenomena were observed ex vivo using excised intact eyes submerged in bacterial suspension [266], suggesting that components within tear fluid are not required for resistance to bacterial adhesion and infection. Eye infection by P. aeruginosa is primarily due to breach of barrier (e.g., scratches on cornea) caused by contact lens immersed in contaminated cleaning solutions, eye trauma and recent ophthalmic surgery. There are more than 140 million contact lens wearers worldwide, with an annualized infection rate between ~2 to ~20 cases per 10,000 wearers. Bacterial keratitis accounts for 90% of all microbial keratitis cases, with P. aeruginosa as the most prevalent pathogen, responsible for anywhere between 23% to >50% cases [267,268]. The intrinsic ability of P. aeruginosa to resist disinfectants and to adhere to plastic surfaces facilitates its introduction and penetration into the compromised corneal epithelium, gaining further entrance into the corneal stroma. Typically, bacterial keratitis cases can be managed by antibiotic treatment, however, if left untreated, may result in perforation, endophthalmitis and loss of vision. Corneal ulcers caused by P. aeruginosa are more severe and difficult to treat, resulting in worse visual impairment [267,269], and may predispose to corneal infection by Streptococcus pneumoniae [270,271]. For a comprehensive review on the role of P. aeruginosa in contact lens-mediated corneal infection, please refer to Fleiszig et al. [272].

As discussed above, intact cornea is resistant to bacterial infection. Most virulence studies in cornea use injury models that bypass the epithelial and basal lamina barriers of cornea and directly deposit bacteria into the stroma [273–275]. However, these models are imprecise because the presence of live/dead P. aeruginosa cells and associated pattern recognition receptor ligands (e.g., LPS, pili, flagellum, outer membrane proteins) could trigger host inflammatory responses and mask the pathogenic potential triggered by other virulence factors [273]. The recently developed contact lens-wearing animal models are expected to circumvent the aforementioned challenges [276]. Nevertheless, “scratched” corneal models of infection have helped to identify
**P. aeruginosa** virulence factors and host immune responses to infection. Below, we summarize various virulence factors of *P. aeruginosa* that are important for corneal infection.

### CELLULAR APPENDAGES AND ADHESINS

#### LPS, T4P and flagella

*P. aeruginosa* initiates infection by binding to receptors on corneal epithelial cells through several “adhesins” including LPS, T4P and flagella. The uptake of *P. aeruginosa* is mediated through the interaction between the outer core of LPS with the cystic fibrosis transmembrane-conductance regulator (CFTR) on lipid rafts, and contributes to persistence, intracellularly survival and disease pathogenesis in the injured murine cornea [277–280]. The LPS-CFTR interaction likely activates PI3K/Akt signaling, leading to the disruption of epithelial cell polarity to promote internalization [281]. In addition to LPS, *P. aeruginosa* uses T4P for adhesion to contact lenses [282] and to sialoglycoprotein receptor of corneal epithelial cells [283,284]. T4P are important for twitching motility-mediated spread, invasion of corneal epithelial cell multilayers, intracellular movement along collagen fiber, and exiting invaded corneal epithelial cells, as well as *in vivo* virulence [266,275,285–288]. Because flagellin is a ligand for the TLR5, it has been difficult to disentangle the virulence roles of flagella and flagellar-mediated motility from immune response generated during flagellin-TLR5 interactions. Nevertheless, various flagellar components including FlhA (flagellar assembly), FliC (flagellin) and FleQ (regulator flagellar gene expression) are important for adhesion and invasion into the corneal epithelial cells [289,290]. Anti-flagellar antibody protects mouse cornea from infection by *P. aeruginosa* [284].

### EXOENZYMES AND SECRETION SYSTEMS

#### T3SS effectors

The ExsA-regulated T3SS effectors (ExoU, ExoS, ExoT, ExoY) are major virulence components of *P. aeruginosa* responsible for cytotoxicity in corneal epithelial cells. Invasive *P. aeruginosa* corneal isolates express ExoS, but not ExoU, with the opposite generally true for cytotoxic isolates [291]. Keratitis isolates tend to favor epidemic clones that express ExoU [292], most likely because they are more resistant to both contact lens disinfection solutions [293], and antimicrobials [294,295]. The activity of RhoGAP domain of ExoT or ExoS alone inhibits the ability of corneal epithelial cells to uptake *P. aeruginosa* bacteria [296]. Additionally, ExoY, which is an adenylate cyclase, is also anti-phagocytic [297]. ExoS and ExoT cause neutrophil apoptosis via their ADP ribosyltransferase activity [298], and ADP-ribosylation of Ras by ExoS promotes *P. aeruginosa* survival in the cornea by blocking neutrophil oxidative burst [299]. Also, ExoS causes membrane blebbing within corneal epithelial cells, which are then utilized as a site for bacterial replication and motility [300]. ExoU is a phospholipase that is required for colonization and disease pathogenesis during corneal infection [301]. ExoU promotes traversal in cultured corneal epithelial cells [302], and *P. aeruginosa* survival in a murine scarification model by modulating survival inside phagocytes and infiltration of immune cells called ring infiltration in cornea of infected animals [303].

#### Proteases

Liquefactive necrosis of the corneal stroma is a major clinical feature of *P. aeruginosa* keratitis. This bacterium secretes multiple proteases that contribute to the pathogenesis of keratitis [304–306]. Injection of purified LasB elastase and alkaline protease into the corneal stroma results in significant tissue necrosis and keratitis [307,308]. Protease IV contributes to the virulence in keratitis by cleaving multiple host defense proteins including immunoglobulins, complements, antimicrobial peptides and surfactant proteins [309]. The *Pseudomonas aeruginosa* small protease (PASP) degrades collagen, a major structural component of the corneal stroma [310]. When injected into rabbit cornea, PASP destroys the epithelium and cause erosions reaching into the stroma. Additionally, the MucD protease promotes *P. aeruginosa* evasion of immune response during keratitis by inhibiting IL-1β, KC and MIP2 production, neutrophil recruitment and enhancing bacterial survival [311]. Among *P. aeruginosa* proteases, it appears that LasA protease is dispensable for corneal infection [312], most likely due to functional redundancy among proteases expressed by the pathogen.

#### ToxA

ToxA disrupts barrier function of corneal epithelial cell monolayers, and exhibits a complementary role with proteases in facilitating *P. aeruginosa* traversal [313].
Direct injection of purified ToxA into the corneal stroma of rabbits caused widespread cell death in a dose-dependent manner [314]. ToxA-deficient mutants were able to induce keratitis as efficiently as their parental wild-type but were more readily cleared by the host, suggesting it plays a role in \textit{P. aeruginosa} persistence during keratitis [315]. Finally, ToxA inhibits synthesis of many proteins including host matrix metalloproteinase 9 (MMP9), while activating other host MMPs in whole rabbit cornea, but the importance of this study is uncertain [304].

**EXOPOLYSACCHARIDES AND BIOFILMS**

**Biofilms**

\textit{P. aeruginosa} can readily form biofilms on contact lenses worn by rats \textit{in vivo} [276,316], and biofilms represent a significant threat to the cornea from several different perspectives, including increased resistance to antimicrobial factors such as those at the ocular surface. \textit{P. aeruginosa} readily forms biofilms in contact lens storage cases and contact lenses, from which they can disperse and continuously reseed the eyes [317]. As noted above c-di-GMP is an intracellular signaling molecule that coordinates the switch from planktonic to biofilm mode of growth by increasing the production of extracellular matrix components (exopolysaccharides, proteins, extracellular DNA) to form the biofilms [318]. Cyclic-di-GMP binds effector proteins, including FleQ that stimulates the expression of \textit{cdr}, \textit{pel}, and \textit{psl} genes that control production of adhesins and exopolysaccharides, critical components for biofilm formation [319]. Importantly, FleQ also regulates \textit{P. aeruginosa} invasion of corneal epithelial cells, with contributions in addition to that of flagellin [290].

**IRON ACQUISITION SYSTEMS**

Iron acquisition plays an important role in ocular infection. Multiple virulence factors important for eye infection, including Protease IV and ToxA are regulated by iron availability and pyoverdine [320]. Accordingly, a pyoverdine biosynthetic mutant (\textit{pvdE}) exhibits poor invasive ability into corneal epithelial cells, and has attenuated virulence in a murine model of keratitis [321].

**BONE AND PERIPROSTHETIC JOINT INFECTIONS**

Orthopedic issues, ranging from bone fractures to joint replacements, are the most common causes of medical care consultation [322], with more than 2.5 million individuals with total hip replacement and 4.7 million individuals with total knee replacement in the United States alone [323]. The demand is expected to increase rapidly with the aging population across the world, and the desire for individuals to stay functional at all ages [324,325]. Periprosthetic joint infection is a devastating complication of total joint arthroplasty and a leading cause of total hip and knee arthroplasty failure [326,327]. Current infection risk reduction approaches to infection include either coating the implant surface with porous or grooved biomaterials to promote soft-tissue ingrowth [328,329], reducing the surface energy to inhibit bacterial adhesion [330–332], or applying layers of antibacterials on the surface to kill the bacteria in vicinity [333–336]. However, implant devices composed of porous materials are associated with a high risk of acute infection in experimental canine and rabbit models [337,338]. Over the longer term, low-energy surfaces become ineffective when a few bacteria attach and eventually form biofilms [339]. Due to elution, tolerance and resistance with recurring use, the efficacy of controlled-release antibiotics will decline overtime [340–342]. Biofilms gradually develop at the abutment-soft tissue interface, leading to recurring and difficult-to-treat infections [343,344]. Superficial infections not only cause pain, erythema, swelling, or purulent discharge at the skin–abutment interface, but could lead to more severe deep infections, and even implant loosening [345].

\textit{P. aeruginosa} is a major pathogen in osteomyelitis and periprosthetic joint infection [346–349]. For example, \textit{P. aeruginosa} causes upward to 75–95\% of infections in patients with skull-based osteomyelitis, which typically arise as a complication of OEM (see above ear infection section) with temporal bone involvement [350]. \textit{P. aeruginosa} and other pseudomonads are also responsible for 3–15\% of reported cases of diabetic foot osteomyelitis [347]. Although most periprosthetic joint infections are caused by methicillin-sensitive and methicillin-resistant staphylococci [348,351,352], Gram-negative bacterial pathogens maintain a moderate proportion (5%-23\%), of these, \textit{P. aeruginosa} is responsible for 25–40\% of reported cases [348,351–354]. Also, \textit{P. aeruginosa} is one of the main pathogens (in addition to \textit{S. aureus} and \textit{S. epidermidis}) involved in soft tissue infections among individuals who undergo osseointegration after limb amputation. Finally, \textit{P. aeruginosa} is a significant cause of septic arthritis, one of the most aggressive joint diseases characterized by rapidly progressing joint and cartilage destruction, with a mortality rate of 5–25\% [355,356]. The incidence of \textit{P. aeruginosa}-mediated septic arthritis is higher in immunocompromised
patients and intravenous drug abusers. Also, septic arthritis caused by *P. aeruginosa* and other Gram-negative bacteria is associated with higher mortality than those involving Gram-positive organisms (25% vs 6%, respectively), with only 20% of patients with septic arthritis triggered by Gram-negative bacteria regaining joint function [357]. Despite its clinical significance, virtually nothing is known about the molecular pathogenesis and virulence factors required for orthopedic infections. Most of the published studies are clinical case reports and reviews.

**BIOFILMS AND SECRETION SYSTEMS**

**Biofilms and T3SS**

Recently, Thompson et al. (2018) have developed a new mouse model of prosthetic joint infection by using titanium implant, which showed bacterial infection of the bone/joint tissue, biofilm formation on the implants, reactive bone changes, and inflammatory immune cell infiltrates [358]. These authors also demonstrated that a bispecific antibody targeting both T3SS translocon protein PcrV and exopolysaccharide biofilm matrix protein PsI successfully reduced the burden *P. aeruginosa* in the joint infection. These findings suggest that both T3SS and biofilms participate in the orthopedic infection by *P. aeruginosa*. The importance of T3SS is further corroborated by finding that cartilages of articular joints, which are anatomical sites rarely infected by bacteria, secrete the cartilage-associated antimicrobial factor (CA-AMF), with significantly more antimicrobial activity against *P. aeruginosa* strains with a functional T3SS. The authors proposed that CA-AMF has evolved to selectively target pathogenic bacteria among the beneficial and commensal microflora [359], though the molecular mechanism such antagonism remains not understood. Finally, a recently developed mouse model of septic arthritis infection by *P. aeruginosa* has revealed a protective role for neutrophils against septic arthritis. In contrast, CD4+ T-cells play pathogenic role in *P. aeruginosa* mediated septic arthritis [360].

**GASTROINTESTINAL TRACT INFECTIONS**

*P. aeruginosa* is usually a transient and not a common pathogen in the gastrointestinal (GI) tract, and isolation of the bacterium in stool is of no clinical significance. However, the presence of *P. aeruginosa* in the proximal intestinal tract is associated with a 70% death rate in critically ill patients, a 3-fold increase over age-matched patients who have negative cultures for this organism [361]. *P. aeruginosa* causes necrotizing enterocolitis in premature infants and in neutropenic cancer patients. For example, *P. aeruginosa* has caused outbreaks of diarrheal diseases in neonatal and pediatric patients [362–364], mostly associated with antibiotic exposure [365,366]. *P. aeruginosa*-mediated neonatal necrotizing enterocolitis are also more frequent in formula-fed newborns [367]. One of the most serious forms of diarrheal diseases caused by *P. aeruginosa* is Shanghai fever, a highly fatal necrotizing enteritis due to rapid onset of septic shock and multiple-organ dysfunction syndrome (MODS) [368]. *P. aeruginosa* also causes infections in individuals who undergo endoscopy. Because endoscopes are made of heat-sensitive materials, they cannot be autoclaved. Endoscopy-related infection by *P. aeruginosa* is typically associated with improper sterilization of reprocessed endoscopes contaminated with gut flora of a patient from previous use [369]. Finally, *P. aeruginosa* is responsible for significant post-surgical infections within the GI tract, and is associated with poor outcome and lack of preoperative oral antibiotic prophylaxis [370–372]. However, very little is known about the virulence mechanisms governing the aforementioned GI-infections.

**QUORUM SENSING**

Besides acting as a QS signal, oxo-C12-HSL disrupts barrier integrity in the human intestinal epithelial Caco-2 cells by activating p38 and p42/44 kinases, resulting in decreased transepithelial electrical resistance, increased paracellular flux, reduction in the expression and distribution of ZO-1 and occludin, and reorganization of F-actin[373]. Oxo-C12-HSL also disrupts epithelial barrier formed by Caco-2 cells by modulating calcium signaling and phosphorylation status of ZO-3 and JAM-A, resulting in reduced expression and distribution of these junction proteins[374]. Oxo-C12-HSL also interacts with the IQ-motif-containing GTPase-activating protein IQGAP1, resulting in changes in the phosphorylation status of Rac1 and Cdc42, altering the cytoskeleton network and inducing migration of Caco-2 cells in a dose- and time-dependent manner[375]. Again, these in vitro observations need to be interpreted with caution as non-physiological concentrations of oxo-C12-HSL were used in the studies using immortalized cell line. A more detailed review of modulation of gut immunity by QS molecules can be found here[376].
CELLULAR APPENDAGES AND ADHESINS

LecA

*P. aeruginosa* can use the LecA lectin to adhere to epithelial surfaces. Binding of purified LecA reduces the tight junction permeability formed by Caco-2 cells. Injection of *P. aeruginosa* or LecA-ToxA cocktail directly into the cecum of mice which previously underwent 30% surgical heptectomy resulted in lethality. Disruption of intestinal tight junction barrier and mouse lethality could be blocked by pretreatment with N-acetyl-D-galactosamine (GalNAc), a receptor for LecA [377,378]. These results indicate that LecA drives the pathogenesis of *P. aeruginosa* in the GI tract by inducing a permeability defect in gut epithelium that allow other virulence factors such as ToxA to penetrate and induce lethality. The expression of LecA is positively regulated by QS, as well as increased by contact with intestinal epithelium and unknown host factors [378]. Interestingly, some of these factors could be the relative concentrations of opioid versus phosphate within the intestinal microenvironment during surgical stress [379].

T4P

Deletion of the pilin-encoding *pilA* gene did not attenuate adhesions to Caco-2 cells, but rather, blocked both penetration and disruption of Caco-2 cell monolayers. Additionally, the T4P were required for injection of the T3SS effector ExoS into host cells [380]. Finally, a PilA-deficient mutant was attenuated in a silkworm model of intestinal infection. Collectively, the aforementioned studies illustrate a pathogenic process where *P. aeruginosa* binds to intestinal epithelium via LecA and uses T4P to facilitate the delivery of virulence factors that disrupt the epithelial barrier.

EXOENZYMES AND SECRETION SYSTEMS

The T3SS effector ExoS mediates the penetration of *P. aeruginosa* through the intestinal epithelial cell barrier. After being injected intracellularly, ExoS binds to, and inactivates, the FXYD domain-containing ion transport regulator 3 (FXYD3), resulting in reduction of Na,K-ATPase activity. Inactivation of Na,K-ATPase inhibits the expression of ZO-1 and occludin, leading to a disruption of the tight junction formed by Caco-2 cells, which allows *P. aeruginosa* to transmigrate effectively through the broken epithelial cell barrier [381].

IRON ACQUISITION SYSTEMS

By comparative genome hybridization analysis of high and low virulence strains, Okuda *et al.* (2012) have identified *P. aeruginosa* genes that are associated with bacterial translocation from the gut epithelial barrier. Among these, the pyoverdine biosynthetic gene *pvdE* is required for penetration through Caco-2 epithelial cell monolayers, and for translocation of *P. aeruginosa* from the gut to the hemolymph in infected silkworms [382]. Analyzing the synergy between PvdE and ExoS revealed that the latter is required for penetration through the intestinal epithelial cell barrier while PvdE is required for virulence and replication in the hemolymph of silkworms, independent of ExoS.

Virulence genes identified through transcriptomic and mutant library screens

Using the insertion-sequencing (INSeq) approach, Skurnik *et al.* (2013) analyzed the contribution to fitness of all non-essential genes in the chromosome of *P. aeruginosa* strain PA14 during GI tract colonization [383]. Mutants with insertion in almost all known virulence factors as well as genes with unknown functions were identified to be putatively attenuated. Interestingly, 90% of these non-essential genes were required for *in vivo* survival following systemic dissemination during neutropenia [383]. However, the results from an earlier study from the same group seem to contradict these results. Koh *et al.* (2010) compared virulence gene expression from the GI tracts of *P. aeruginosa*-colonized mice to that from the drinking water used to colonize the mice. The expression of genes involved in biofilm formation and T3SS were significantly increased during gut colonization. However, none of the biofilm formation genes were required for GI colonization in the Tn mutant library screen. Similarly, T3SS mutants deficient in ExoS, ExoU, ExoT, and PopB were dispensable for GI colonization and neutropenia-induced dissemination in mice, suggesting that changes in the gene expression during GI colonization is not predictive of an essential role for the gene product in either colonization or overall survival following induction of neutropenia [384].

In a separate study, it was found that monosaccharides present in formula versus those in human milk also appear to modulate the expression of *P. aeruginosa* virulence genes, which may have implication in the
pathogenesis of neonatal necrotizing enterocolitis. Arabinose (present in formula), xylose (present in human milk), and galactose (present in both formula and feces from milk-fed infants) caused a significant increase in the expression of virulence genes. In contrast, mannose (present in the feces of milk-fed infants) significantly attenuated the expression of virulence genes [367]. In another study, mucin glycoproteins, which are major components of mucus lining the GI tract and forms the first line of defense against microbial infection, were shown to downregulate the expression of virulence genes that are involved in QS, siderophore biosynthesis and toxin secretion, as well as rapidly disintegrate biofilms in an in vitro 3D mucus model [385]. Similar to the aforementioned studies, the importance of P. aeruginosa virulence genes would have to be authenticated through single infection in order to clarify their roles in GI infection. However, in a Caenorhabditis elegans model of intestinal infection, P. aeruginosa seems to have evolved a strategy to exploit host mucin to derive monosaccharides required for a successful infection [386]. Again, these studies underscore the complexity of host–pathogen interactions between P. aeruginosa and GI tract, and a caution is in order to properly interpret results from various experiments.

**URINARY TRACT INFECTIONS (UTI)**

Urinary tract infections (UTI) are caused by multiple bacterial species and can be community-acquired or nosocomial. Among health care-associated infections, UTI are the most common after surgical site infections and pneumonia. P. aeruginosa itself only represents about 5 to 10% of those reported UTI [387]. However, among patients with a complicated UTI, outcomes are usually worst when infected with P. aeruginosa [388]. Most P. aeruginosa-driven UTI are hospital-acquired through the use of urinary catheters, causing catheter-associated UTI (CAUTI). These infections are characterized by the formation of surface-associated biofilm inside indwelling catheters, leading to an entryway to the urinary tract. From there, P. aeruginosa can colonize the bladder and reach the kidneys. (The role of P. aeruginosa virulence factors in UTI has been reviewed recently [387], and more extensively but slightly dated[388]). Being the versatile pathogen that it is, P. aeruginosa uses multiple-virulence factors to facilitate its survival in the human host. In term of UTI, no specific virulence factor has been described as strictly required for these infections. However, most isolates obtained from UTI are notably proficient at forming biofilms, at producing exoproteases (LasB, AprA) and at causing hemolysis [389].

**EXOPOLYSACCHARIDES AND BIOFILMS**

**BIOFILMS**

The formation of biofilms appears to be a main feature of P. aeruginosa CAUTI, as this phenotype is enhanced in CAUTI isolates compared to those from UTI [390]. The biofilm matrix in CAUTI seems to rely more on extracellular DNA secretion than polysaccharide; this was clearly shown as a Pel- Psl-null double mutant was still capable of colonizing its hosts in a CAUTI mouse model in a manner dependent on extracellular DNA (i.e., sensitive to DNase treatments) [391]. Alginate production is specifically reduced in UTI biofilms, a clear contrast to the biofilms formed in the lungs of CF patients, where isolated strains are often mucoid because they overproduce alginate [392]. Those differences could be linked to the composition of urine: a study combining transcriptomics, proteomics and metabolomics of P. aeruginosa PAO1 biofilms grown in artificial urine medium revealed a reduction in alginate synthesis and an increase in the transcription of Fur-regulated genes – including siderophores pyoverdine and pyochelin – compared to biofilms grown in diluted Lysogeny Broth (LB) medium [393]. This study also reported various metabolic adaptations such as reduced denitrification, increased amino acid metabolism and increased expression of QS-regulated virulence factors (proteases LasB and AprA, the lipase LipA and the LecA when grown in artificial urine [393].

**QUORUM SENSING**

While QS-null mutants were capable of dissemination through the urinary tract of infected mice, they failed to colonize the organs (bladder and kidney) and cause tissue damage, and were instead rapidly cleared [394–396]. In contrast, this seems to not be the case for CAUTI: another study highlights that QS-null mutants of strain PA14 can colonize the urinary tract as effectively as the wild type in a CAUTI mouse model [397]. The authors also report a reduced expression of QS-related genes when P. aeruginosa was grown in PBS-Tryptone combined with human urine; adding urea to the culture medium also reduced the expression of QS-related virulence factors without affecting acyl-homoserine lactone (AHL) production, instead reducing the detection of AHL by their cognate receptors.
LasR and RhlR [397]. Such a divergence in requirement for QS might depend on the mode of infection, as QS appears to be more important in regulating virulence factors involved in acute vs chronic infections.

**IRON ACQUISITION SYSTEMS**

Because urine is recognized as a low-iron environment [398], it is not surprising that siderophore production would be a key virulence determinant of *P. aeruginosa* UTI. The importance of siderophore is highlighted by multiple studies that characterized the *in vitro* production of virulence factors of *P. aeruginosa* isolates from UTI. About 2.5% and 7.5% of 121 *P. aeruginosa* UTI isolates were deficient in pyochelin and pyoverdine production, respectively, when grown under iron-depleted conditions [399]; none of 30 isolates were deficient in pyoverdine production from another study [390]. For the same reason, isolates from UTI often display a proteolytic potential *in vitro* [389]. Proteases such as the LasB and the AprA facilitate iron scavenging by disrupting transferrin – a common iron-bound proteins in urine [142,400].

**EXOENZYMES AND SECRETION SYSTEMS**

**Hemolysins**

High production of hemolysin might be another factor facilitating the colonization of the urinary tract: Mittal et al. measured the activity of multiple virulence factors *in vitro* between urine isolates and assessed their virulence in a mouse model of acute ascending pyelonephritis. They reported a positive correlation between the hemolytic activity and the bacterial load and tissue damage in this model [401]. In a study where virulence determinants of clinical isolates from different infection sites were quantified and compared *in vitro*, isolates from urine had more phospholipase C activity compared to isolates from other infection sites. There were also reduced amounts of ExoS activity produced by urine isolates compared to most other sampling sites, but increased elastase activity compared to blood isolates [402]. In contrast, in another similar study, *P. aeruginosa* isolates from the urinary tract of patients had a pronounced increase in ExoS activity measured *in vitro* compared to tracheal and wound isolates, along with lower ToxA activity. No differences were reported in the activity levels of LasB elastase and phospholipase C between the different groups of isolates [403].

**Pyocyanin**

Pyocyanin, the characteristic blue phenazine of *P. aeruginosa*, seems to be less important in the setting of UTI, with an overall lower prevalence of production among isolates from UTI, according to different studies [389,393]. Despite its low reported occurrence, one study described the cytotoxic effects that pyocyanin has on renal tubular epithelial cell when a concentration of pyocyanin ranging between 30 and 60 μM was added to the growth medium: a rise in endoplasmic reticulum vacuolization and proteotoxicity attributed to the strong redox potential of pyocyanin [404].

In summary, to properly colonize the urinary tract of its host, *P. aeruginosa* relies on its capability to form a biofilm and scavenge iron from the scarce environment of the urine. Reliance on QS-regulated virulence factors seems restricted to dissemination of bacteria to upper organs.

**BLOOD-RELATED INFECTIONS**

Blood-related infection occurs mostly among patients in intensive-care units and among immunocompromised individuals. Currently, *Pseudomonas* spp. represent a significant cause of hospital-acquired bacteremia, being the third leading cause of Gram-negative bloodstream infections (BSI) [405]. Several studies indicate an increased risk of mortality among patients with *P. aeruginosa* BSI, as compared with the risk for similar patients with other Gram-negative bacteria infections [406]. BSI start when *P. aeruginosa* breaks the epithelial barrier of an affected organ such as lungs, urinary tract or gastrointestinal tract to enter the bloodstream. Central venous catheters can also act as entry points. This often leads to dissemination toward other organs and sepsis, with poorer outcome compared to other bacterial species [406]. Occasionally, this bacterium also causes endocarditis, but occurrence is only significant among intravenous drug users and patients with heart prosthetics [9,407]. Notably, endocarditis can be defined as either left-sided (aortic and mitral valve vegetation) and right-sided (tricuspid valve vegetation), both sides will contain different environmental conditions that will affect the outcome of the infective endocarditis – with left-sided infection linked to poorer outcome [408].

**Prevalence of virulence factors**

The high mortality rate of *P. aeruginosa* BSI has been mostly linked to inappropriate initial antimicrobial
EXOENZYMES AND SECRETION SYSTEMS

T3SS and elastase

To reach the bloodstream from an infected organ, *P. aeruginosa* needs to traverse the epithelial barrier of the organ and the endothelium of the adjacent blood vessel. To that end, *P. aeruginosa* will use T3SS and its effectors to induce tissue damage [15]. ExoU is a potent toxin with an intracellular phospholipase activity akin to the human phospholipase A2 that will induce plasma membrane disruption upon translocation into the cytosol of host’s epithelial cells [418]. An *exoU*-positive genotype is an independent predictor of early mortality in *P. aeruginosa* BSI [415]. ExoS and ExoT are both proteins containing GTPase-activating domain and ADPRT domain inhibiting the actin cytoskeleton and leading to cell death [15]. The role of ExoS in the dissemination from the alveolar epithelium through the endothelium of blood vessels into the blood stream is already reviewed elsewhere [419]. In short, ExoS will partner with the LasB elastase: the former will cause damage to the epithelial cells while the latter – given access to the endothelium of the blood vessel – will cleave vascular endothelium cadherin and disrupt anchor between neighboring cells by damaging tight junction-associated proteins. Apart from T3SS-mediated toxicity, other factors contribute to the damage that *P. aeruginosa* can cause to the tissue.

EXOPOLYSACCHARIDES AND BIOFILMS

Alginate

In the case of endocarditis, only a few studies report the role of certain virulence factors. By comparing the virulence of a mucoid *P. aeruginosa* strain and a non-mucoid variant in a rabbit endocarditis model, Bayer *et al.* (1992) demonstrated that the mucoid strain resisted antibiotic treatment and killing by polymorphonuclear leukocytes much better than its non-mucoid counterpart, resistance that was abolished with the injection of alginase[420].
with intrathecal injection showing the best outcome with adequate antibiotics [11,422].

EXOENZYMES AND SECRETION SYSTEMS

T3SS

There have been association between neurodegenerative diseases and the presence of P. aeruginosa. During acute pneumonia, patients were found to have an increased amount of amyloid β and tau protein in their cerebrospinal fluid and bronchoalveolar lavages [423]. Reduction of amyloid β 42 and increase in phosphorylated tau proteins in the cerebrospinal fluid are biomarkers of the development of neurological disorders such as dementia and Alzheimer’s disease [424]. Both exoenzymes ExoU and ExoY induce phosphorylation of tau protein, each with a distinct mechanism [153]. ExoY acts as an adenylate cyclase that causes the phosphorylation of tau through the AMPc-dependent protein kinase A and its release from microtubules [425–427]. ExoU is a phospholipase that releases arachidonic acid after its enzymatic cleavage of a phospholipid, which was shown to induce polymerization of tau in vitro [428,429]. Additional research is needed to further characterized the role of various virulence factors in this organ.

SKIN AND SOFT TISSUE INFECTIONS

Our skin serves as the first barrier against the entry of external pathogens. However, once injured – through heavy burns or other wounds – bacterial colonization becomes possible. P. aeruginosa causes a variety of skin and soft tissue infections ranging from benign to life-threatening, and it is an especially common pathogen of skin in burn wound, surgical wounds and diabetic foot ulcers. While burn wound infections are often considered acute and lead to rapid dissemination into the bloodstream and lethal sepsis, surgical wounds and ulcer-related infections are considered chronic infections that persist for longer time [430].

WOUND AND BURN WOUND INFECTIONS

EXOPOLYSACCHARIDES AND BIOFILMS

Biofilms

P. aeruginosa is a prevalent pathogen in burn wound infections, accounting for about 30% of reported cases [431]. An important factor for chronic P. aeruginosa infection of the skin is the formation of a biofilm. Using a model of full thickness scald burn wound rat model, Brandenburg et al. (2019) observed a bacterial biofilm that is produced on the burned skin by P. aeruginosa [432]. They quantified an elevated expression of alg and pel from this biofilm, which indicates to importance of both exopolysaccharides in the composition of skin biofilm.

QUORUM SENSING

Mutants in the main components of the las and rhl QS systems were much less virulent in an acute burn mouse model [433]. Interestingly, loss of these QS systems does not abolish biofilm formation on the skin of burned mice, nor colonization around blood vessels, as demonstrated with electron and confocal microscopy [434].

EXOENZYMES AND SECRETION SYSTEMS

Volatiles metabolites

Wounds heavily infected with P. aeruginosa have a distinctive odor resembling grape. This odor is caused by the volatile metabolite 2-aminoacetophenone [435], that is used by P. aeruginosa to promote its chronic infection phenotype [436], including through immunomodulation [437].

Pyocyanin

It seems that P. aeruginosa can sense the damaged state of wounds, as a recent study demonstrated that growth with homogenized fascia – the collagen-rich connective tissue that envelops muscles – significantly induces the production of pyocyanin and the transcription of pyochelin biosynthesis genes [438]. Another study quantified the amount of pyocyanin from burn wound exudates to assess its importance in tissue damage. The levels of pyocyanin reached up to 5.3 µg per grams of exudates [439]. When similar concentrations of pyocyanin were applied to human fibroblasts, it caused a reduction in tissue repair and cell doubling rate.

CELLULAR APPENDAGES AND ADHESINS

Flagella and T4P

Turner et al. (2014) used Tn-Seq to assess the fitness determinants in acute burn and chronic wound infection of a mouse model [430]. They identified flagellar motility and chemotaxis as important for the fitness of
P. aeruginosa PAO1 in the burn wound setting, while T3SS and T6SS were important factors in the chronic wound model. T4P and Psl production were required in both infection types to maintain a high fitness. Using RNA-seq, they also highlighted that iron acquisition gene, T2SS and T3SS are upregulated in vivo – in both acute and chronic models – compared to lab-grown planktonic bacteria. LPS modification clusters were downregulated in both infection settings, especially in the chronic wound model [430]. In addition, metabolic transcription profiles indicated that growth in wounds relies on long chain fatty acids metabolism, mutants incapable of catabolizing such carbon source having a virulence defect in both mouse models. This study highlighted the physiological differences that occur depending of the infection caused by P. aeruginosa. The importance of flagella and pili assembly genes had previously been demonstrated in a burn wound mouse model, where mutants unable to form either (or both) flagellum and T4P had reduced lethality and dissemination to other organs [440,441]. Indeed, the flagellum has been implicated as a major virulence determinant in normal epidermis tissue invasion: flagellin-null mutants – but not T2SS or T3SS mutants – were unable to penetrate and invade the epithelial layer during infection of reconstructed human epithelium. This was confirmed in mouse model of sub-cutaneous infection [442].

**Virulence genes revealed by transcriptomic approach**

Because bloodstream infections often occur after a severe burn trauma, Kruczek et al. (2016) compared transcription profile of P. aeruginosa PA14 between growth in whole blood from a healthy volunteer and from three severe burn victims [443]. Iron acquisition genes were amongst the most affected in their regulation: transcription of ferrous uptake genes and pyochelin synthesis genes, but not pyoverdine, was markedly increased. On the other hand, QS-regulated genes were under-expressed in whole blood from burn victims compared to the healthy individual. Pilin and fimbrae genes were downregulated, but flagellum genes were upregulated, suggesting activation of flagellar motility by the blood of burned patients compared to the blood of healthy volunteers. It appears from these studies that QS, iron uptake and motility systems play major roles in the unfolding of burned skin infections.

Another study used RNA-seq to evaluate changes in the transcription profile of P. aeruginosa PAO1 when grown in burn wound exudates [444]. Under these culture conditions, iron-acquisition and heme-import clusters were upregulated. In addition, T6SS was upregulated while T3SS was downregulated. The transcription of genes involved in QS and its related virulence factors was activated very early during growth in burn wound exudates. By comparing the chemical composition of the medium before and after the growth of P. aeruginosa, the authors noticed that triglycerides, cholesterol and lactate were consumed first [444].

**CHRONIC FOOT ULCERS**

**BIOFILMS, EXOENZYMES AND SECRETION SYSTEM**

Prevention of wound healing is a trait of chronic skin infection. Biofilm formation delays tissue repair of chronic diabetic foot ulcers, venous leg ulcers and pressure ulcers [445,446]. Infecting a biopsy-punch wound of diabetic mice with biofilm-grown P. aeruginosa delayed wound healing from 4 weeks to 6–8 weeks compared to uninfected wounds [447]. Both LasB elastase and protease IV reduced wound repair through the inhibition of cell migration and angiogenesis [448]. Both proteases were better produced by high biofilm-forming strains isolated from diabetic foot ulcers compared to moderate or low biofilm-forming isolates from the same infection site. This impact on wound healing was demonstrated by treating mouse wounds with each purified proteases [448]. Jacobsen et al. (2012) also demonstrated that P. aeruginosa wild-type supernatant – but not supernatant from double lasR- rhlR- QS mutant – impaired cell migration of keratinocytes and fibroblasts [449]. The T3SS apparatus also plays a role in these infections. T3SS was demonstrated to contribute to the delay in wound healing in a diabetic mouse model [450].

**FOLLICULITIS**

**BIOFILMS, SECRETION SYSTEM AND CELLULAR APPENDAGES**

Finally, maybe the most common P. aeruginosa infection is a skin rash: this pathogen causes hot tub dermatitis, a condition characterized by a folliculitis that frequently afflicts users of pools and hot tubs [451]. This community-acquired skin infection results from the colonization of hair follicles following exposure to contained, contaminated water (e.g., whirlpools, swimming pools, water slides, bathtubs). Normally benign, such infections can evolve in immunocompromised individuals into severe ecthyma gangrenosum, expressed as gangrenous ulcers with erythematous borders [452]. There is close to no information on the virulence factors required to induce folliculitis and
dermatitis. Intriguingly, *P. aeruginosa* serotype O11 was shown to be very prevalent in these types of skin infections [453,454]. Although they were predominant in whirlpool water, these isolates were not more resistant to chlorine [454]. However, we know that the ability to form stress-resistant biofilms is a feature required for the colonization of plumbing fixtures in whirlpool recirculation systems [455]. Furthermore, *P. aeruginosa* isolates secreting ExoU are frequently serotyped as O11 and typically isolated from acute infections [456]. Maybe not surprisingly, a correlation was found between the O11 serotype, positivity for *exoU* and novel *pilA* type in a collection of corneal ulcer isolates with good twitching motility [457]. In a sub-cutaneous infection model, exoenzyme ExoU was shown to be required to induce formation of abscesses in healthy mice, but not in neutropenic mice. The authors suggested that inhibition of neutrophils through the T3SS might be the cornerstone of bacterial growth and tissue invasion in skin diseases [458].

**FUTURE PERSPECTIVES**

Tremendous amount of advances have been achieved in the understanding of *P. aeruginosa* pathogenesis over the last few decades. What are the opportunities and challenges lying ahead in the age of “omics”? Some of these major challenges, with a focus on specific tissues and organs are: 1) direct *in vivo* analysis of the expression of key virulence factors during infection of specific organs; 2) direct analysis of the *P. aeruginosa* virulence process and its interactions with host cells through the initiation of an infection to resolution of the disease in tissues and organs. These challenges can now be addressed by using *in vivo* and single-cell transcriptomics, and by three-dimensional bioprinting of so-called primitive human lungs combined with comparative transcriptomics profiling of healthy versus diseased primitive lung constructs.

Direct *in vivo* *P. aeruginosa* transcriptomics has been attempted using different strategies and identified hundreds of genes specifically expressed during infection but not *in vitro* [459]. For example, Conforth et al. (2018) compared the *P. aeruginosa* gene expression patterns of clinical samples analyzed directly with *apriori* no growth *in vitro* from CF sputum, chronic wound infections, and burned wound infections, or *in vivo* mouse models of acute pneumonia, burn infections or surgical wound infections. These authors found that transcriptomic profiles of *P. aeruginosa* genes obtained from murine surgical wound model was more closely resembled those of human infections. In contrast, the transcriptomic profiles of *P. aeruginosa* genes in murine models of acute pneumonia and burn sepsis more resembled *in vitro* gene expression profiles. Additionally, some of the genes were not so-called typical virulence factors but instead *lexA* (SOS stress response), *mex* (efflux pumps), *fisH* (protease), *ZnuABC* (bacterial growth), *faoAB* (long-chain fatty-chain metabolism), and a collection of hypothetical genes [460].

The analysis of within-host evolution of *P. aeruginosa* and other bacterial pathogens is now possible by using single-cell transcriptomics, and may lead to the prediction of clinical progression of bacterial infections and options in therapy [461]. For example, single-cell RNA sequencing was used to examine immune cell dysfunction in the pathogenesis of bacterial pneumonia-derived sepsis [462]. A combined strategy could be used by following gene expression of *P. aeruginosa* lung infections using micro-biopsied lung samples and single bacterial cells isolated from tissues by laser microdissection. Although challenging, these technologies are constantly improving and excellent trajectory is being made in single-cell genomics and transcriptome profiling, which will offer different insights into bacterial pathogenesis over metagenomic approaches [426].

It is well known that, in many cases, data acquired through animal models do not faithfully recapitulate various human lung pathologies and diseases, including CF [463]. Due to major genotypic, phenotypic and metabolic differences, novel therapeutics derived from animal models do not always translate into efficacy in humans [464]. In addition, classical cell culture approaches lack the complexity and tissue-like structures relevant to detailed biological analysis. Recent progress and feasibility has been obtained in development of organs-on-a-chip [465], and new technologies that pave the way for 3D bioprinting of complex tissues, including human skin, cartilage, bone, and the air-blood barrier [466,467]. Even though human lungs contain a repertoire of more than 60 specialized cells, we have initiated the next level of lung 3D bioprinting and transcriptomics profiling by focusing on lung epithelial and alveolar cells, leading to a systematic scaling-up approach for additional lung cells and vascularized constructs (Kukavica-Ibrulj I, Potvin, M. and Levesque R. C., unpublished). Another area of advances is in the development of organoids derived from human pluripotent stem cells to model organ development and disease pathogenesis, including in the context of lung–pathogen interactions [468–470]. Combining these new advances with newly developed high-definition spatial transcriptomics [471,472] that can be
coupled with single-cell analysis \[473,474\] to perform \textit{in situ} profiling of infected organs and tissues will be highly desirable. Additionally, implementation of the novel integrative multi-omics approaches to acquire, analyze, and model multimodal data will facilitate disentanglement of the influences of genetic, environment, immune status, (post)transcriptional, (post)translational, and metabolic processes driving the initiation and resolution of disease pathogenesis \[475,476\].

Finally, antibodies against single \textit{P. aeruginosa} epitopes have been examined for a long time, but without satisfactory protective efficacy. In recent years, there has been an effort to develop bispecific monoclonal antibody (mAb) that simultaneously targets two surface epitopes on \textit{P. aeruginosa}. Significantly, when administered prophylactically or post-infection, the bispecific mAb targeting a component of the T3SS translocon PcrV and the biofilm exopolysaccharide Psl protected against mouse models of lethal acute pneumonia \[477\], and joint infection \[358\]. Additionally, when administered either prophylactically or post-infection, subtherapeutic dose of bispecific mAb synergized with subtherapeutic doses of the antibiotics to protect mice in a lethal pneumonia model \[477\]. Importantly, similar efficacy was achieved by using a DNA delivery method, which circumvents the hurdles of traditional mAb delivery through direct, \textit{in vivo} immunoglobulin production \[478\]. Finally, in contrast to the broad-spectrum antibiotic approach, pathogen-specific targeting with therapeutic bispecific mAbs would leave the beneficial microbiota intact.

Overall, the aforementioned approaches will expand the current frontiers in our understanding of \textit{P. aeruginosa} pathogenic processes and host responses in tissues and organs.

CONCLUSIONS

In summary, many years of dedicated research has significantly advanced our understanding of \textit{P. aeruginosa} pathogenesis, especially in the context of chronic lung infections in CF (Figure 1). However, much is still to be revealed about the virulence mechanisms in the rest of organ systems. Because of its ubiquitous presence in the environment, metabolic versatility, high intrinsic resistance to different types of chemotherapeutic agents and antibiotics, and large repertoire of virulence arsenals, \textit{P. aeruginosa} is a very difficult pathogen to control and will likely persist as a significant clinical challenge to modern medicine for many years to come. Therefore, more in-depth understanding of \textit{Pseudomonas} virulence regulation, development of novel antimicrobial approaches, better antibiotic stewardship, as well as vaccine development are warranted. Development of novel animal models that better mimic \textit{P. aeruginosa} infectious diseases of humans as well as rapid advances in the new "omics" technologies will greatly advance these challenges. Particularly, major increase in the understanding in the molecular and cellular events governing free living planktonic mode of growth to biofilm formation, and transition from acute infection to chronic colonization may drive novel anti-\textit{Pseudomonas} approaches.

ACKNOWLEDGMENTS

We thank Justin Parker of the University of Illinois College of Veterinary Medicine for assistance with figure illustration. C. D.M. holds a Ph.D. scholarship from the Fonds de Recherche du Québec– Nature et Technologies (FRQ-NT). Work in the E.D. laboratory is funded by the Canada Research Chairs Program, the Canadian Institute for Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC). Work in the R.C.L. laboratory is funded by the Canadian Institute for Health Research (CIHR), Cystic Fibrosis Canada, CIHR-Joint Programming Initiative on Antimicrobial Resistance (IPIAMR), Fonds de Recherche Santé Québec (FRQS)-Respiratory Health Network (QRHN), Genome Canada, Génome Québec and Ontario Genomics. Work in the G.W.L. laboratory is funded by grants from the United States National Institute of Health (R01HL090699, R01AI080710 and R01HL142626) and the American Lung Association DeSouza Research Award (DS-192835-N).

FUNDING

This work was supported by the American Lung Association [DS-192835-N]; Canada Research Chairs; Cystic Fibrosis Canada; Genome Canada; National Heart, Lung, and Blood Institute [R01 HL090699 and R01 HL142626]; National Institute of Allergy and Infectious Diseases [R01 AI080710-06A1]; Natural Sciences and Engineering Research Council of Canada; Canadian Institute for Health Research; Génome Québec and Ontario Genomics; CIHR-Joint Programming Initiative on Antimicrobial Resistance (IPIAMR); Canadian Institute for Health Research (CIHR); Fonds de Recherche Santé Québec (FRQS)-Respiratory Health Network (QRHN).

AUTHOR CONTRIBUTIONS

C.D.M., E.D., J.G., R.C.L., and G.W.L., cowrote and edited the manuscript.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

No potential conflict of interest was reported by the authors.
**DATA AVAILABILITY STATEMENT**

Data sharing not applicable – no new data generated.

**References**

[1] Gaynes R, Edwards JR. National Nosocomial Infections Surveillance S. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848–854.

[2] Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37 (11):1288–1301.

[3] Murphy TF. *Pseudomonas aeruginosa* in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2009;15(2):138–142.

[4] Folkesson A, Jelsbak L, Yang L, et al. Adaptation of *Pseudomonas aeruginosa* to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol. 2012;10(12):841–851.

[5] Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309–317.

[6] Lyt U-C, Hekimian G, Kouleuti D, et al. Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia. Curr Opin Crit Care. 2018;24(5):332–338.

[7] Barbier F, Andremont A, Wolff M, et al. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med. 2013;19 (3):216–228.

[8] Gellaty SL, Hancock REW. *Pseudomonas aeruginosa*: new insights into pathogenesis and host defenses. Pathog Dis. 2013;67(3):159–173.

[9] Lin T-I, Huang Y-F, Liu P-Y, et al. *Pseudomonas aeruginosa* infective endocarditis in patients who do not use intravenous drugs: analysis of risk factors and treatment outcomes. J Microbiol Immunol Infect. 2016;49(4):516–522.

[10] Venkatesan A, Spalding C, Speedie A, et al. *Pseudomonas aeruginosa* infective endocarditis presenting as bacterial meningitis. J Infect. 2005;51(4):199–202.

[11] Rodriguez-Lucas C, Fernandez J, Martinez-Sela M, et al. *Pseudomonas aeruginosa* nosocomial meningitis in neurological patients with intraventricular catheters: therapeutic approach and review of the literature. Enfermedades Infecciosas Y Microbiologia Clinica. 2020;38(2):54–58.

[12] Lee K, Yoon SS. *Pseudomonas aeruginosa* Biofilm, a Programmed Bacterial Life for Fitness. J Microbiol Biotechnol. 2017;27(6):1053–1064.

[13] Filloux A. Protein Secretion Systems in *Pseudomonas aeruginosa*: an Essay on Diversity, Evolution, and Function. Front Microbiol. 2011;2:155.

[14] Pena RT, Blasco L, Ambroa A, et al. Relationship Between Quorum Sensing and Secretion Systems. Front Microbiol. 2019;10:1100.

[15] Galle M, Carpentier I, Beyaert R. Structure and function of the Type III secretion system of *Pseudomonas aeruginosa*. Current Protein and Peptide Science. 2012;13(8):831–842.

[16] Elsen S, Huber P, Boullot S, et al. A type III secretion negative clinical strain of *Pseudomonas aeruginosa* employs a two-partner secreted exolysin to induce hemorrhagic pneumonia. Cell Host Microbe. 2014;15(2):164–176.

[17] Sana TG, Berni B, Bleves S. The T6SSs of *Pseudomonas aeruginosa* Strain PA01 and Their Effectors: beyond Bacterial-Cell Targeting. Front Cell Infect Microbiol. 2016;6:661.

[18] Lau GW, Hassett DJ, Ran H, et al. The role of pyocyanin in *Pseudomonas aeruginosa* infection. Trends Mol Med. 2004;10(12):599–606.

[19] Abdel-Mawgoud AM, Hausmann R, Lépine F, et al. Rhamnolipids: detection, characterization, biosynthesis, genetic regulation and bioengineering of production. In: Soberón-Chávez G, editor. Biosurfactants: from genes to applications. Berlin, Heidelberg: Springer; 2011. p. 13–55.

[20] Soberon-Chavez G, Gonzalez-Valdez A, Soto-Aceves MP, et al. Rhamnolipids produced by *Pseudomonas*: from molecular genetics to the market. Microbiotechnol. 2021;14(1):136–146.

[21] Fuqua C, Parsek MR, Greenberg EP. Regulation of gene expression by cell-to-cell communication: acyl-homoserine lactone quorum sensing. Annu Rev Genet. 2001;35(1):439–468.

[22] Williams P, Winzer K, Chan WC, et al. Look who’s talking: communication and quorum sensing in the bacterial world. Philos Trans R Soc Lond B Biol Sci. 2007;362(1483):1119–1134.

[23] Ahator SD, Zhang L. Small Is Mighty—Chemical Communication Systems in *Pseudomonas aeruginosa*. Annu Rev Microbiol. 2019;73(1):559–578.

[24] Diggle SP, Whiteley M. Microbe Profile: *Pseudomonas aeruginosa*: opportunistic pathogen and lab rat. Microbiology. 2020;166(1):30–33.

[25] Juhás M, Eberl L, Tummler B. Quorum sensing: the power of cooperation in the world of *Pseudomonas*. Environ Microbiol. 2005;7(4):459–471.

[26] Déziel E, Lépine F, Milot S, et al. Analysis of *Pseudomonas aeruginosa* 4-hydroxy-2-alkylquinolines (HAQs) reveals a role for 4-hydroxy-2-heptylquinoline in cell-to-cell communication. Proc Natl Acad Sci USA. 2004;101:1339–1344.

[27] Pesci EC, Milbank JBJ, Pearson JP, Pesci EC, Milbank JBJ, Pearson JP, McKnight S, Kende AS, Greenberg EP, et al. Quinolone signaling in the cell-to-cell communication system of *Pseudomonas aeruginosa*. Proc Natl Acad Sci USA. 1999;96 (20):11229–11234.

[28] Gallagher LA, McKnight SL, Kuznetsova MS, et al. Functions required for extracellular quinolone signaling by *Pseudomonas aeruginosa*. J Bacteriol. 2002;184 (23):6472–6480.

[29] Xiao G, Déziel E, He J, et al. MvfR, a key *Pseudomonas aeruginosa* pathogenicity LTTR-class regulatory
protein, has dual ligands. Mol Microbiol. 2006;62 (6):1689–1699.

[30] Schertzer JW, Brown SA, Whiteley M. Oxygen levels rapidly modulate Pseudomonas aeruginosa social behaviours via substrate limitation of PqsH. Mol Microbiol. 2010;77(6):1527–1538.

[31] Wade DS, Calfee MW, Rocha ER, Wade DS, Calfee MW, Rocha ER, Ling EA, Engstrom E, Coleman JP, et al. Regulation of Pseudomonas quinolone signal synthesis in Pseudomonas aeruginosa. J Bacteriol. 2005;187(13):4372–4380.

[32] Bjarnsholt T, Givskov M. The role of quorum sensing in the pathogenicity of the cunning aggressor Pseudomonas aeruginosa. Anal Bioanal Chem. 2007;387(2):409–414.

[33] Rumbaugh KP, Griswold JA, Hamood AN. The role of quorum sensing in the in vivo virulence of Pseudomonas aeruginosa. Microbes Infect. 2000;2 (14):1721–1731.

[34] Smith RS, P. aeruginosa quorum-sensing systems and virulence. Curr Opin Microbiol. 2003;6(1):56–60.

[35] Hentzer M, Wu H, Andersen JB, et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 2003;22(15):3803–3815.

[36] Wagner VE, Bushnell D, Passador L, et al. Microarray Analysis of Pseudomonas aeruginosa Quorum-Sensing Regulons: effects of Growth Phase and Environment. J Bacteriol. 2003;185(7):2080–2095.

[37] Whiteley M, Lee KM, Greenberg EP. Identification of genes controlled by quorum sensing in Pseudomonas aeruginosa. Proc Natl Acad Sci USA. 1999;96 (24):13904–13909.

[38] Jimenez PN, Koch G, Thompson JA, et al. The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiol Mol Biol Rev. 2012;76(1):46–65.

[39] Gambello MJ, Iglewski B. Cloning and characterization of the Pseudomonas aeruginosa lasR gene, a transcriptional activator of elastase expression. J Bacteriol. 1991;173(9):3000–3009.

[40] Brint JM, Ohman DE. Synthesis of multiple exoprodu cts in Pseudomonas aeruginosa is under the control of RhlR-RhlII, another set of regulators in strain PA01 with homology to the autoinducer-responsive LuxR-Lux family. J Bacteriol. 1995;177(24):7155–7163.

[41] Ochsner UA, Reiser J. Autoinducer-mediated regulation of rhhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. Proc Natl Acad Sci USA. 1995;92(14):6424–6428.

[42] Davies DG, Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science. 1998;280(5361):295–298.

[43] Lesic B, Starkey M, He J, et al. Quorum sensing differentially regulates Pseudomonas aeruginosa type VI secretion locus I and homologous loci II and III, which are required for pathogenesis. Microbiology. 2009;155(9):2845–2855.

[44] Sana TG, Hachani A, Bucior I, et al. The second type VI secretion system of Pseudomonas aeruginosa strain PA01 is regulated by quorum sensing and Fur and modulates internalization in epithelial cells. J Biol Chem. 2012;287(32):27095–27105.

[45] Cornelis P, Dingemans J. Pseudomonas aeruginosa adapts its iron uptake strategies in function of the type of infections. Front Cell Infect Microbiol. 2013;3:75.

[46] Otero-Asman JR, García-Garcia AI, Civantos C, et al. Pseudomonas aeruginosa possesses three distinct systems for sensing and using the host molecule haem. Environ Microbiol. 2019;21(12):4629–4647.

[47] Herlihey FA, Clarke AJ. Controlling Autolysis During Flagella Insertion in Gram-Negative Bacteria. Adv Exp Med Biol. 2017;925:41–56.

[48] Burrows LL. Pseudomonas aeruginosa Twitching Motility: type IV Pili in Action. Annu Rev Microbiol. 2012;66(1):493–520.

[49] Giraud C, De Bentzmann S. Inside the complex regulation of Pseudomonas aeruginosa chaperone usher systems. Environ Microbiol. 2012;14(8):1805–1816.

[50] Imberty A, Wimmerova M, Mitchell EP, et al. Structures of the lectins from Pseudomonas aeruginosa: insights into the molecular basis for host glycan recognition. Microbes Infect. 2004;6(2):221–228.

[51] Huczkynski SM, Lam JS, Khursigara CM. The Role of Pseudomonas aeruginosa Lipopolysaccharide in Bacterial Pathogenesis and Physiology. Pathogens. 2020;9(1):6.

[52] Tata PR, Rajagopal J. Plasticity in the lung: making and breaking cell identity. Development. 2017;144 (5):755–766.

[53] Travaglini KJ, Nabhan AN, Penland L, et al. A molecular cell atlas of the human lung from single-cell RNA sequencing. Nature. 2020;587 (7855):619–625.

[54] Putter F, Denney L, Gregory LG, et al. Pulmonary environmental cues drive group 2 innate lymphoid cell dynamics in mice and humans. Sci Immunol. 2019;4(36):eaav7638.

[55] Button B, Cai L-H, Ehre C, et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science. 2012;337 (6097):937–941.

[56] Sheehan JK, Kesimer M, Pickles R. Innate immunity and mucus structure and function. Novartis Found Symp. 2006;279:155–66.

[57] Ehre C, Worthington EN, Liesman RM, et al. Overexpressing mouse model demonstrates the protective role of Muc5ac in the lungs. Proc Natl Acad Sci U S A. 2012;109(41):16528–16533.

[58] Roy MG, Livraghi-Butrico A, Fletcher AA, et al. Muc5b is required for airway defence. Nature. 2014;505 (7483):412–416.

[59] Bonser LR, Zlock I, Finkbeiner W, et al. Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma. J Clin Invest. 2016;126 (6):2367–2371.

[60] Rose MC, Vojnow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev. 2006;86(1):245–278.

[61] Tilley AE, Walters MS, Shaykhiev R, et al. Gila dysfunction in lung disease. Annu Rev Physiol. 2015;77 (1):379–406.

[62] Choi W, Choe S, Lau GW. Inactivation of FOXA2 by Respiratory Bacterial Pathogens and Dysregulation of
Pulmonary Mucus Homeostasis. Front Immunol. 2020;11:515.

[63] Malhotra S, Hayes D Jr., Wozniak DJ. Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clin Microbiol Rev. 2019;32(3).

[64] Burns JL, Gibson RL, McNamara S, et al. Longitudinal Assessment of Pseudomonas aeruginosa in Young Children with Cystic Fibrosis. J Infect Dis. 2001;183 (3):444–452.

[65] Quaderi SA, Hurst JR. The unmet global burden of COPD. Global Health, Epidemiology and Genomics. 2018;3:e4.

[66] Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523–532.

[67] Eissner MD, Anthonisen N, Coutsas D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(5):693–718.

[68] Thompson WH, St-Hilaire S. Prevalence of chronic obstructive pulmonary disease and tobacco use in veterans at Boise Veterans Affairs Medical Center. Respir Care. 2010;55(5):555–560.

[69] Sood A, Petersen H, Blanchette CM, et al. Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. Am J Respir Crit Care Med. 2010;182 (9):1098–1104.

[70] Brulotte CA, Lang ES. Acute exacerbations of chronic obstructive pulmonary disease in the emergency department. Emergency Medicine Clinics of North America. 2012;30(2):223–247, vii.

[71] Anzueto A, Miravitlles M. Chronic Obstructive Pulmonary Disease Exacerbations: a Need for Action. Am J Med. 2018;131(9):15–22.

[72] Rodrigo-Troyano A, Melo V, Marcos PJ, et al. Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease Patients with Frequent Hospitalized Exacerbations: a Prospective Multicentre Study. Respiration. 2018;96(5):417–424.

[73] Doring G, Parameswaran IG, Murphy TF. Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease. FEMS Microbiol Rev. 2011;35(1):124–146.

[74] Jensen PO, Kolpen M, Kragh KN, et al. Microenvironmental characteristics and physiology of biofilms in chronic infections of CF patients are strongly affected by the host immune response. APMIS. 2017;125(4):276–288.

[75] Martin DW, Schurr MJ, Mudd MH, et al. Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Natl Acad Sci U S A. 1993;90(18):8377–8381.

[76] Starkey M, Hickman JH, Ma L, et al. Pseudomonas aeruginosa rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung. J Bacteriol. 2009;191(11):3492–3503.

[77] Li Z, Kosorok MR, Farrell PM, et al. Longitudinal Development of Mucoid Pseudomonas aeruginosa Infection and Lung Disease Progression in Children With Cystic Fibrosis. JAMA. 2005;293(3):581–588.

[78] Hodges NA, Gordon CA. Protection of Pseudomonas aeruginosa against ciprofloxacin and beta-lactams by homologous alginate. Antimicrob Agents Chemother. 1991;35(11):2450–2452.

[79] Hengzhuang W, Wu H, Ciofu O, et al. Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2011;55(9):4469–4474.

[80] Leid JG, Willson CJ, Shirliff ME, et al. The Exopolysaccharide Alginate Protects Pseudomonas aeruginosa Biofilm Bacteria from IFN-γ-Mediated Macrophage Killing. J Immunol. 2005;175 (11):7512–7518.

[81] Malhotra S, Limoli DH, English AE, Parsek MR, Wozniak DJ. Mixed Communities of Mucoid and Nonmucoid Pseudomonas aeruginosa Exhibit Enhanced Resistance to Host Antimicrobials. mBio. 2018;9(2):e00275–18.

[82] Malhotra S, Hayes D Jr., Wozniak DJ, Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung. J Cyst Fibros. 2019;18 (6):796–803.

[83] DeVries CA, Ohman DE. Mucoid-to-nonnucoid conversion in alginate-producing Pseudomonas aeruginosa often results from spontaneous mutations in algT, encoding a putative alternate sigma factor, and shows evidence for autoregulation. J Bacteriol. 1994;176 (21):6677–6687.

[84] Price CE, Brown DG, Limoli DH, et al. Exogenous Alginate Protects Staphylococcus aureus from Killing by Pseudomonas aeruginosa. J Bacteriol. 2020;202(8):e00559–19.

[85] Chattoraj SS, Murthy R, Ganesan S, et al. Pseudomonas aeruginosa alginate promotes Burkholderia cenocepacia persistence in cystic fibrosis transmembrane conduc-tance regulator knockout mice. Infect Immun. 2010;78 (3):984–993.

[86] Jones AM. Which pathogens should we worry about? Paediatr Respir Rev. 2019;31:15–17.

[87] Evans TJ. Small colony variants of Pseudomonas aeru-ginosa in chronic bacterial infection of the lung in cystic fibrosis. Future Microbiology. 2015;10 (2):231–239.

[88] Von götz F, Häussler S, Jordan D, et al. Expression analysis of a highly adherent and cytotoxic small colony variant of Pseudomonas aeruginosa isolated from a lung of a patient with cystic fibrosis. J Bacteriol. 2004;186(12):3837–3847.

[89] Rohde M. Small-colony variants of Pseudomonas aeru-ginosa in cystic fibrosis. Clin Infect Dis. 1999;29 (3):621–625.

[90] Pestrak MJ, Chaney SB, Eggleston HC, et al. Pseudomonas aeruginosa rugose small-colony variants evade host clearance, are hyper-inflammatory, and persist in multiple host environments. PLoS Pathog. 2018;14(2):e1006842.

[91] Gifford AH, Willger SD, Dolben EL, et al. Use of a Multiplex Transcrip Method for Analysis of Pseudomonas aeruginosa Gene Expression Profiles in the Cystic Fibrosis Lung. Infect Immun. 2016;84 (10):2995–3006.
[119] Singh PK, Schafer AL, Parsek MR, Singh PK, Schafer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000;407(6805):762–764.

[120] Chambers CE, Visser MB, Schwab U, et al. Identification of N-acylhomoserine lactones in mucopurulent respiratory secretions from cystic fibrosis patients. FEMS Microbiol Lett. 2005;244(2):297–304.

[121] Zhang S, McCormack FX, Levesque RC, et al. The flagellum of Pseudomonas aeruginosa is required for resistance to clearance by surfactant protein A. PLoS One. 2007;2(6):e564.

[122] Kuang Z, Hao Y, Hwang S, et al. The Pseudomonas aeruginosa flagellum confers resistance to pulmonary surfactant protein-A by impacting the production of exoproteases through quorum-sensing. Mol Microbiol. 2011;79(5):1220–1235.

[123] Balloy V, Verma A, Kuravi S, et al. The Role of Flagellin versus Motility in Acute Lung Disease Caused by Pseudomonas aeruginosa. J Infect Dis. 2007;196(2):289–296.

[124] Lilheøj EP, Kim BT, Kim KC. Identification of Pseudomonas aeruginosa flagellin as an adhesin for Muc1 mucin. Am J Physiol Lung Cell Mol Physiol. 2002;282(4):L751–6.

[125] Comolli JC, Hauser AR, Waite L, et al. Pseudomonas aeruginosa gene products PilT and PilU are required for cytotoxicity in vitro and virulence in a mouse model of acute pneumonia. Infect Immun. 1999;67(7):3625–3630.

[126] Tan RM, Kuan Z, Hao Y, et al. Type IV pilus glycosylation mediates resistance of Pseudomonas aeruginosa to opsonic activities of the pulmonary surfactant protein A. Infect Immun. 2015;83(4):1339–1346.

[127] Kus JV, Tullis E, Cvikovitch DG, et al. Significant differences in type IV pilin allele distribution among Pseudomonas aeruginosa isolates from cystic fibrosis (CF) versus non-CF patients. Microbiology (Reading). 2004;150(5):1315–1326.

[128] O'Toole GA, Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol. 1998;30(2):295–304.

[129] Bucior I, Pielage JF, Engel JN. Pseudomonas aeruginosa pili and flagella mediate distinct binding and signaling events at the apical and basolateral surface of airway epithelium. PLoS Pathog. 2012;8(4):e1002616.

[130] Lorenz A, Preusse M, Bruchmann S, et al. Importance of flagella in acute and chronic Pseudomonas aeruginosa infections. Environ Microbiol. 2019;21(3):883–897.

[131] Lovewell RR, Patankar YR, Berwin B. Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol. 2014;306(7):L591–603.

[132] Tart AH, Blanks MJ, Wozniak DJ. The AlgT-dependent transcriptional regulator AmrZ (AlgZ) inhibits flagellum biosynthesis in mucoid, non-motile Pseudomonas aeruginosa cystic fibrosis isolates. J Bacteriol. 2006;188(18):6483–6489.

[133] Cohen TS, Prince AS. Activation of inflammasome signaling mediates pathology of acute P. aeruginosa pneumonia. Journal of Clinical Investigation. 2013;123(4):1630–1637.

[134] Chemani C, Imbery A, De Bentzmann S, et al. Role of LecA and LecB lectins in Pseudomonas aeruginosa-induced lung injury and effect of carbohydrate ligands. Infect Immun. 2009;77(5):2065–2075.

[135] Zheng S, Eierhoff T, Aigal S, et al. The Pseudomonas aeruginosa lectin LecA triggers host cell signalling by glycosphingolipid-dependent phosphorylation of the adaptor protein CrkII. Biochim Biophys Acta Mol Cell Res. 2017;1864(7):1236–1245.

[136] Diggie SP, Stacey RE, Dodd C, et al. The galactophilic lectin, LecA, contributes to biofilm development in Pseudomonas aeruginosa. Environ Microbiol. 2006;8(6):1095–1104.

[137] Tielker D, Hacker S, Loris R, et al. Pseudomonas aeruginosa lectin LecB is located in the outer membrane and is involved in biofilm formation. Microbiology (Reading). 2005;151(5):1313–1323.

[138] Passos Da Silva D, Matwichuk ML, Townsend DO, et al. The Pseudomonas aeruginosa lectin LecB binds to the exopolysaccharide PsI and stabilizes the biofilm matrix. Nat Commun. 2019;10(1):2183.

[139] Thuenauer R, Landi A, Trefzer A, et al. The Pseudomonas aeruginosa Lectin LecB Causes Integrin Internalization and Inhibits Epithelial Wound Healing. mBio. 2020;11(2):e03260–19.

[140] Cott C, Thuenauer R, Landi A, et al. Pseudomonas aeruginosa lectin LecB inhibits tissue repair processes by triggering β-catenin degradation. Biochim Biophys Acta. 2016;1863(6):1106–1118.

[141] Bardooel BW, Van Der Ent S, Pel MJC, et al. Pseudomonas evades immune recognition of flagellin in both mammals and plants. PLoS Pathog. 2011;7(8):e1002206.

[142] Kim S-J, Park R-Y, Kang S-M, et al. Pseudomonas aeruginosa alkaline protease can facilitate siderophore-mediated iron-uptake via the proteolytic cleavage of transferrins. Biol Pharm Bull. 2006;29(11):2295–2300.

[143] Kuang Z, Hao Y, Walling BE, Kuang Z, Hao Y, Walling BE, Jeffries JL, Ohman DE, Lau GW. Pseudomonas aeruginosa elastase provides an escape from phagocytosis by degrading the pulmonary surfactant protein-A. PLoS One. 2011;6(11):e27091.

[144] Chapon-Hervé V, Akrim M, Latifi A, et al. Regulation of the xcp secretion pathway by multiple quorum-sensing modulons in Pseudomonas aeruginosa. Mol Microbiol. 1997;24(6):1169–1178.

[145] Shaver CM, Hauser AR. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect Immun. 2004;72(12):6969–6977.

[146] Vance RE, Rietsch A, Mekalansos J. Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PA01 in vivo. Infect Immun. 2005;73(3):1706–1713.

[147] Diaz MH, Hauser AR. Pseudomonas aeruginosa cytotoxic ExoU is ejected into phagocytic cells during acute pneumonia. Infect Immun. 2010;78(4):1447–1456.
[148] Howell HA, Logan LK, Hauser AR. Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia. mBio. 2013;4(2):e00032–13.

[149] Janjua HA, Segata N, Bernabo P, et al. Clinical populations of Pseudomonas aeruginosa isolated from acute infections show a wide virulence range partially correlated with population structure and virulence gene expression. Microbiology (Reading). 2012;158 (8):2089–2098.

[150] Tingpej P, Smith L, Rose B, et al. Phenotypic characterization of clonal and nonclonal Pseudomonas aeruginosa strains isolated from lungs of adults with cystic fibrosis. J Clin Microbiol. 2007;45 (6):1697–1704.

[151] Munder A, Rothschu J, Schirmer B, et al. The Pseudomonas aeruginosa ExoY phenotype of high-copy-number recombinants is not detectable in natural isolates. Open Biol. 2018;8(1):170250.

[152] Stevens TC, Ochoa CD, Morrow KA, et al. The Pseudomonas aeruginosa exoenzyme Y impairs endothelial cell proliferation and vascular repair following lung injury. Am J Physiol Lung Cell Mol Physiol. 2014;306(10):L915–24.

[153] Morrow KA, Ochoa CD, Balczen R, et al. Pseudomonas aeruginosa exoenzymes U and Y induce a transmissible endothelial proteinopathy. Am J Physiol Lung Cell Mol Physiol. 2016;310(4):L337–53.

[154] Galle M, Jin S, Bogaert P, et al. The Pseudomonas aeruginosa Type III Secretion System Has an Exotoxin S/T/Y Independent Pathogenic Role during Acute Lung Infection. PLoS One. 2012;7(7):e41547.

[155] Bertrand Q, Job V, Maillard AP, et al. Exolysin (ExlA) from Pseudomonas aeruginosa Punctures Holes into Target Membranes Using a Molten Globule Domain. J Mol Biol. 2020;432(16):4466–4480.

[156] Bouillot S, Munro P, Gallet B, et al. Pseudomonas aeruginosa Exolysin promotes bacterial growth in lungs, alveolar damage and bacterial dissemination. Sci Rep. 2017;7(1):2120.

[157] Russell AB, LeRoux M, Hathazi K, et al. Diverse type VI secretion phospholipases are functionally plastic antibacterial effectors. Nature. 2013;496 (7446):508–512.

[158] Jiang F, Waterfield NR, Yang J, et al. A Pseudomonas aeruginosa type VI secretion phospholipase D effector targets both prokaryotic and eukaryotic cells. Cell Host Microbe. 2014;15(5):600–610.

[159] Wilderman PJ, Vasili AI, Johnson Z, et al. Genetic and biochemical analyses of a eukaryotic-like phospholipase D of Pseudomonas aeruginosa suggest horizontal acquisition and a role for persistence in a chronic pulmonary infection model. Mol Microbiol. 2001;39 (2):291–303.

[160] Fujita K, Akino T, Yoshioka H. Characteristics of heat-stable extracellular hemolysin from Pseudomonas aeruginosa. Infect Immun. 1988;56(5):1385–1387.

[161] Johnson MK, Boese-Marranzo D. Production and properties of heat-stable extracellular hemolysin from Pseudomonas aeruginosa. Infect Immun. 1980;29 (3):1028–1033.

[162] Kurioka S, Liu PV. Effect of the hemolysin of Pseudomonas aeruginosa on phosphatidylcholine and on phospholipase C activity. J Bacteriol. 1967;93 (2):670–674.

[163] Sierra G. Hemolytic effect of a glycolipid produced by Pseudomonas aeruginosa. Antonie Van Leeuwenhoek. 1960;26(1):189–192.

[164] Stutts MJ, Schwab JH, Chen MG, et al. Effects of Pseudomonas aeruginosa on bronchial epithelial ion transport. Am Rev Respir Dis. 1986;134(1):17–21.

[165] Kownatzki R, Tummler B, Doring G. Rhamnolipid of Pseudomonas aeruginosa in sputum of cystic fibrosis patients. Lancet. 1987;329(8540):1026–1027.

[166] Read RC, Roberts P, Munro N, et al. Effect of Pseudomonas aeruginosa rhamnolipids on mucociliary transport and ciliary beating. J Appl Physiol. 1992;72 (6):2271–2277.

[167] Kohler T, Guanella R, Carlet J, et al. Quorum sensing-dependent virulence during Pseudomonas aeruginosa colonisation and pneumonia in mechanically ventilated patients. Thorax. 2010;65(8):703–710.

[168] Van Gennip M, Christensen LD, Albede M, et al. Inactivation of the rhaA gene in Pseudomonas aeruginosa prevents rhamnolipid production, disabling the protection against polymorphonuclear leukocytes. APMIS. 2009;117(7):537–546.

[169] Hingley S, Hastie A, Kueppers F, et al. Effect of cilio-static factors from Pseudomonas aeruginosa on rabbit respiratory cilia. Infect Immun. 1986;51(1):254–262.

[170] Kanthakumar K, Taylor GW, Candell DR, et al. The effect of bacterial toxins on levels of intracellular adenosine nucleotides and human ciliary beat frequency. Pulmonary Pharmacology. 1996;9(4):223–230.

[171] Fung DC, Somerville M, Richardson PS, et al. Mucus glycoconjugate complexes released from feline trachea by a bacterial toxin. Am J Respir Cell Mol Biol. 1995;12 (3):296–306.

[172] Somerville M, Taylor G, Watson D, et al. Release of Mucous Glycoconjugates by Pseudomonas aeruginosa Rhamnolipids into Feline Trachea In Vivo and Human Bronchus In Vitro. Am J Respir Cell Mol Biol. 1992;6(1):116–122.

[173] Graham A, Steel DM, Wilson R, et al. Effects of purified Pseudomonas rhamnolipids on bioelectric properties of sheep tracheal epithelium. Exp Lung Res. 1993;19(1):77–89.

[174] Wallace CJ, Medina SH, ElSayed MEH. Effect of rhamnolipids on permeability across Caco-2 cell monolayers. Pharm Res. 2014;31(4):887–894.

[175] Zulianello L, Canard C, Köhler T, et al. Rhamnolipids are virulence factors that promote early infiltration of primary human airway epithelia by Pseudomonas aeruginosa. Infect Immun. 2006;74(6):3134–3147.

[176] Halldorsson S, Gudjonsson T, Gottfredsson M, et al. Azithromycin Maintains Airway Epithelial Integrity during Pseudomonas aeruginosa Infection. Am J Respir Cell Mol Biol. 2010;42(1):62–68.

[177] Aranda FJ, Espuny MJ, Marques A, et al. Thermodynamics of the Interaction of a Dirhamnolipid Biosurfactant Secreted by Pseudomonas aeruginosa with Phospholipid Membranes. Langmuir. 2007;23(5):2700–2705.
phosphatidylcholine membranes. Int J Pharm. 2006;325(1-2):99–107.

[179] McClure CD, Schiller NL. Inhibition of macrophage phagocytosis by Pseudomonas aeruginosa rhamnolipids in vitro and in vivo. Curr Microbiol. 1996;33 (2):109–117.

[180] McClure CD, Schiller NL. Effects of Pseudomonas aeruginosa rhamnolipids on human monocyte-derived macrophages. J Leukoc Biol. 1992;52(2):97–102.

[181] Jensen PO, Bjarnsholt T, Phipps R, et al. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology. 2007;153 (5):1329–1338.

[182] Shryock TR, Silver SA, Banschbach MW, et al. Effect of Pseudomonas aeruginosa rhamnolipid on human neutrophil migration. Curr Microbiol. 1984;10(6):323–328.

[183] Bergmann U, Scheffer J, Koller M, et al. Induction of inflammatory mediators (histamine and leukotrienes) from rat peritoneal mast cells and human granulocytes by Pseudomonas aeruginosa strains from burn patients. Infect Immun. 1989;57(7):2187–2195.

[184] Konig B, Bergmann U, Konig W. Induction of inflammatory mediator release (serotonin and 12-hydroxyecosatetraenoic acid) from human platelets by Pseudomonas aeruginosa glycolipid. Infect Immun. 1992;60(8):3150–3155.

[185] Bédard M, McClure CD, Schiller NL, et al. Release of Interleukin-8, Interleukin-6, and Colony-stimulating Factors by Upper Airway Epithelial Cells: implications for Cystic Fibrosis. Am J Respir Cell Mol Biol. 1993;9 (4):455–462.

[186] Nickzad A, Déziel E. The involvement of rhamnolipids in microbial cell adhesion and biofilm development - an approach for control? Lett Appl Microbiol. 2014;58 (5):447–453.

[187] Boles BR, Thoendel M, Singh PK. Rhamnolipids mediate detachment of Pseudomonas aeruginosa from biofilms. Mol Microbiol. 2005;57(5):1210–1223.

[188] Déziel E, Lépine F, Milot S, et al. rhlA is required for the production of a novel biosurfactant promoting swarming motility in Pseudomonas aeruginosa: 3-(3-hydroxyalkanoyloxy)alkanoic acids (HAAs), the precursors of rhamnolipids. Microbiology. 2003;149 (8):2005–2013.

[189] Neu TR. Significance of bacterial surface-active compounds in interaction of bacteria with interfaces. Microbiol Rev. 1996;60(1):151–166.

[190] Pamp SJ, Tolker-Nielsen T. Multiple roles of biosurfactants in structural biofilm development by Pseudomonas aeruginosa. J Bacteriol. 2007;189 (6):2531–2539.

[191] Schooling SR, Charaf UK, Allison DG, et al. A role for rhamnolipid in biofilm dispersion. Biofilms. 2004;1 (2):91–99.

[192] Davey ME, Caiazza NC, O'Toole GA. Rhamnolipid surfactant production affects biofilm architecture in Pseudomonas aeruginosa PA01. J Bacteriol. 2003;185 (3):1027–1036.

[193] Wilson R, Sykes DA, Watson D, et al. Measurement of Pseudomonas aeruginosa phenazine pigments in sputum and assessment of their contribution to sputum sol toxicity for respiratory epithelium. Infect Immun. 1988;56(9):2515–2517.

[194] Hunter RC, Klepac-Ceraj V, Lorenzi MM, et al. Phenyazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity. Am J Respir Cell Mol Biol. 2012;47(6):738–745.

[195] Forteza R, Lauredo IT, Burch R, et al. Extracellular metabolites of Pseudomonas aeruginosa produce bronchoconstriction by different mechanisms. Am J Respir Crit Care Med. 1994;149(3):687–693.

[196] Lauredo IT, Sabater JR, Ahmed A, et al. Mechanism of pyocyanin- and 1-hydroxyphenazine-induced lung neutrophilia in sheep airways. J Appl Physiol. 1985;1998(85):2298–2304.

[197] Munro NC, Barker A, Rutman A, et al. Effect of pyocyanin and 1-hydroxyphenazine on in vivo tracheal mucus velocity. J Appl Physiol. 1985;1989(67):316–323.

[198] Dormehl I, Ras G, Taylor G, et al. Effect of Pseudomonas aeruginosa-derived pyocyanin and 1-hydroxyphenazine on pulmonary mucociliary clearance monitored scintigraphically in the baboon model. International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology. 1991;18(5):455–459.

[199] Lau GW, Ran H, Kong F, et al. Pseudomonas aeruginosa pyocyanin is critical for lung infection in mice. Infect Immun. 2004;72(7):4275–4278.

[200] Caldwell CC, Chen Y, Goetzmann HS, et al. Pseudomonas aeruginosa exotoxin pyocyanin causes cystic fibrosis airway pathogenesis. Am J Pathol. 2009;175(6):2473–2488.

[201] Han W, Kaestner HK, Ang S-L, et al. Foxa2 regulates alveolarization and goblet cell hyperplasia. Development. 2004;131(4):953–964.

[202] Hao Y, Kuang Z, Walling BE, Hao Y, Kuang Z, Walling BE, Bhatia S, Sivaguru M, Chen Y, et al. Pseudomonas aeruginosa pyocyanin causes airway goblet cell hyperplasia and metaplasia and mucus hypersecretion by inactivating the transcriptional factor FoxA2. Cell Microbiol. 2012;14(3):401–415.

[203] Rada B, Gardina P, Myers TG, et al. Reactive oxygen species mediate inflammatory cytokine release and EGFR-dependent mucin secretion in airway epithelial cells exposed to Pseudomonas pyocyanin. Mucosal Immunol. 2011;4(2):158–171.

[204] Choi W, Yang AX, Waltenburg MA, et al. FOXA2 depletion leads to mucus hypersecretion in canine airways with respiratory diseases. Cell Microbiol. 2019;21 (1):e12957.

[205] Choi W, Choe S, Lin J, et al. Exendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPARγ-FoxA2-phosphatase signaling. Mucosal Immunol. 2020;13(4):637–651.

[206] Hao Y, Kuang Z, Xu Y, Hao Y, Kuang Z, Xu Y, Walling BE, Lau GW. Pyocyanin-induced mucin production is associated with redox modification of FoxA2. Respir Res. 2013;14(1):82.

[207] Damron FH, Oglesby-Sherrouse AG, Wilks A, et al. Dual-seq transcriptomics reveals the battle for iron during Pseudomonas aeruginosa acute murine pneumonia. Sci Rep. 2016;6(1):39172.
[208] Hunt TA, Peng W-T, Loubens I, et al. The Pseudomonas aeruginosa alternative sigma factor PvdS controls exotoxin A expression and is expressed in lung infections associated with cystic fibrosis. Microbiology (Reading). 2002;148(10):3183–3193.

[209] Banin E, Vasil ML, Greenberg EP. From The Cover: iron and Pseudomonas aeruginosa biofilm formation. Proc Natl Acad Sci U S A. 2005;102(31):11076–11081.

[210] Beare PA, For RJ, Martin LW, et al. Siderophore-mediated cell signalling in Pseudomonas aeruginosa: divergent pathways regulate virulence factor production and siderophore receptor synthesis. Mol Microbiol. 2003;47(1):195–207.

[211] Ochsner UA, Johnson Z, Lamont IL, et al. Exotoxin A production in Pseudomonas aeruginosa requires the iron-regulated pvdS gene encoding an alternative sigma factor. Mol Microbiol. 1996;21(5):1019–1028.

[212] Minandri F, Imperi F, Frangipani E, et al. Role of Iron Uptake Systems in Pseudomonas aeruginosa Virulence and Airway Infection. Infect Immun. 2016;84(8):2324–2335.

[213] Oemeg IS, Ollila OH, Iwai H. NMR structure of the C-terminal domain of TonB protein from Pseudomonas aeruginosa. PeptJ. 2018;6:e5412.

[214] Kang D, Revtovich AV, Chen Q, et al. Pyoverdine-Dependent Virulence of Pseudomonas aeruginosa Isolates From Cystic Fibrosis Patients. Front Microbiol. 2019;10:2048.

[215] Andersen SB, Marvig RL, Molin S, et al. Long-term social dynamics drive loss of function in pathogenic bacteria. Proc Natl Acad Sci U S A. 2015;112(34):10756–10761.

[216] Nguyen AT, O’Neill MJ, Watts AM, et al. Adaptation of iron homeostasis pathways by a Pseudomonas aeruginosa pyoverdine mutant in the cystic fibrosis lung. J Bacteriol. 2014;196(12):2265–2276.

[217] Gabrielaite M, Johansen HK, Molin S, et al. Gene Loss and Acquisition in Lineages of Pseudomonas aeruginosa Evolving in Cystic Fibrosis Patient Airways. mBio. 2020;11(5):e02359–20.

[218] Colque CA, Albarracin Orio AG, Feliziani S, et al. Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients. Antimicrob Agents Chemother. 2020;64(5):e02142–19.

[219] Nolan LM, Turnbull L, Katrib M, et al. Pseudomonas aeruginosa is capable of natural transformation in biofilms. Microbiology (Reading). 2020;166(10):995–1003.

[220] San Millan A, Toll-Riera M, Qi Q, et al. Integrative analysis of fitness and metabolic effects of plasmids in Pseudomonas aeruginosa PA01. ISME J. 2018;12(12):3014–3024.

[221] Del Barrio-Tofino E, Lopez-Causape C, Oliver A. Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update. Int J Antimicrob Agents. 2020;56(6):106196. update.

[222] Freschi L, Vincent AT, Jeukens J, et al. The Pseudomonas aeruginosa Pan-Genome Provides New Insights on Its Population Structure, Horizontal Gene Transfer, and Pathogenicity. Genome Biol Evol. 2019;11(1):109–120.

[223] Martinez-Solano L, Macia MD, Fajardo A, et al. Chronic Pseudomonas aeruginosa Infection in Chronic Obstructive Pulmonary Disease. Clin Infect Dis. 2008;47(12):1526–1533.

[224] Ngo CC, Massa HM, Thornton RB, et al. Predominant Bacteria Detected from the Middle Ear Fluid of Children Experiencing Otitis Media: a Systematic Review. PLoS One. 2016;11(3):e0150949.

[225] Nogues JC, Pérez-Losada M, Preciado D. Review of otitis media microbiome studies: what do they tell us? Laryngoscope Investigative Otolaryngology. 2020;5(5):936–940.

[226] Thornton RB, Hakansson A, Hood DW, et al. Panel 7 – pathogenesis of otitis media – a review of the literature between 2015 and 2019. Int J Pediatr Otorhinolaryngol. 2020;130(Suppl 1):109838.

[227] Verhoef M, Van Der Veen EL, Rovers MM, et al. Chronic suppurrative otitis media: a review. Int J Pediatr Otorhinolaryngol. 2006;70(1):1–12.

[228] Mittal R, Lisi CV, Gerring R, et al. Current concepts in the pathogenesis and treatment of chronic suppurrative otitis media. J Med Microbiol. 2015;64(10):1103–1116.

[229] Smith JA, Danner CJ. Complications of Chronic Otitis Media and Cholesteatoma. Otolaryngol Clin North Am. 2006;39(6):1237–1255.

[230] Roland PS, Stroman DW. Microbiology of acute otitis externa. The Laryngoscope. 2002;112(7):1166–1177.

[231] Schaefer P, Baugh RF. Acute otitis externa: an update. Am Fam Physician. 2012;86(11):1055–1061.

[232] Carfrae MJ, Kesser BW. Malignant otitis externa. Otolaryngol Clin North Am. 2008;41(3):vii–ix.

[233] Long DA, Koyfman A, Long B. An emergency medicine-focused review of malignant otitis externa. Am J Emerg Med. 2020;38(8):1671–1678.

[234] Hafidh MA, Keogh I, Walsh RM, et al. Otogenic intracranial complications. a 7-year retrospective review. Am J Otolaryngol. 2006;27:390–395.

[235] Malagutti N, Rotondo JC, Cerritelli L, et al. High Human Papillomavirus DNA loads in Inflammatory Middle Ear Diseases. Pathogens. 2020;9(3):224.

[236] Avidano MA, Cotter CS, Stringer SP, et al. Analysis of protease activity in human otitis media. Otolaryngol Head Neck Surg. 1998;119(4):346–351.

[237] Jin CS, Hamaguchi Y, Sakakura Y. ELISA to Determine Immunoreactive Pseudomonas aeruginosa Elastase in Chronic Suppurative Otitis Media. Int Arch Allergy Appl Immunol. 1991;96(3):193–198.

[238] Cotter CS, Avidano MA, Stringer SP, et al. Inhibition of proteases in Pseudomonas otitis media in chinchillas. Otolaryngol Head Neck Surg. 1996;115(4):342–351.

[239] Park M-H, Kim SY, Roh EY, et al. Difference of Type 3 secretion system (T3SS) effector gene genotypes (exoU and exoS) and its implication to antibiotics resistances in isolates of Pseudomonas aeruginosa from chronic otitis media. Auris Nasus Larynx. 2017;44(3):258–265.

[240] Lundman L, Harada T, Santi PA, et al. Inner Ear Damage and Passage through the round Window Membrane of Pseudomonas aeruginosa Exotoxin a in a Chinchilla Model. Ann Otol Rhinol Laryngol. 1992;101(3):437–444.
[241] Stenqvist M, Anniko M, Rask-Andersen H. Middle ear mucosa changes following exposure to Pseudomonas aeruginosa exotoxin A. Eur Arch Otorhinolaryngol. 1999;256(10):484–490.
[242] Yunus TM, Molina RM, Prevatt AR, et al. Hearing loss with semicircular canal fistula in exotoxin A-resistant Pseudomonas otitis media. Otolaryngol Head Neck Surg. 2004;130(4):430–436.
[243] Reimer. Concentrations of the Pseudomonas aeruginosa toxin pyocyanin in human ear secretions. Acta Oto-Laryngologica. 2000;120(543):86–88.
[244] Elsheikh MN, Mahfouz ME. Up-regulation of MUC5AC and MUC5B mucin genes in nasopharyngeal respiratory mucosa and selective up-regulation of MUC5B in middle ear in pediatric otitis media with effusion. The Laryngoscope. 2006;116(3):365–369.
[245] Samuels TL, Yan JC, Khampa P, et al. Association of Gel-Forming Mucins and Aquaporin Gene Expression With Hearing Loss, Effusion Viscosity, and Inflammation in Otitis Media With Effusion. 2017;143(8):810–817.
[246] Preiado D, Goyal S, Rahimi M, et al. MUC5B Is the predominant mucin glycoprotein in chronic otitis media fluid. Pediatr Res. 2010;68(3):231–236.
[247] Lee MR, Pawlowski KS, Luong A, et al. Biofilm presence in humans with chronic suppurative otitis media. Otolaryngol Head Neck Surg. 2009;141(5):567–571.
[248] Gu X, Keyoumey Y, Long L, et al. Detection of bacterial biofilms in different types of chronic otitis media. Eur Arch Otorhinolaryngol. 2014;271(11):2877–2883.
[249] Hall-Stoodley L, Hu FZ, Gieseke A, et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. Jama. 2006;296(2):202–211.
[250] Dohar JE, Hebda PA, Veeh R, et al. Mucosal biofilm formation on middle-ear mucosa in a nonhuman primate model of chronic suppurative otitis media. The Laryngoscope. 2005;115(8):1469–1472.
[251] Byrd MS, Pang B, Hong W, et al. Direct evaluation of Pseudomonas aeruginos biosl biofilm mediators in a chronic infection model. Infect Immun. 2011;79(8):3087–3095.
[252] Chole RA, Gagnon PM, Vogel JP. Inactivation of specific Pseudomonas aeruginosa biofilm factors does not alter virulence in infected cholesteatomas. Otol Neurotol. 2014;35(9):1585–1591.
[253] Kao WTK, Gagnon PM, Vogel JP, et al. FleQ, a Transcriptional Activator, Is Required for Biofilm Formation In Vitro But Does Not Alter Virulence in a Cholesteatoma Model. Otol Neurotol. 2016;37(7):977–983.
[254] Jung JY, Lee DH, Wang EW, et al. P. aeruginosa infection increases morbidity in experimental cholesteatomas. Laryngoscope. 2011;121:2449–2454.
[255] Yadav MK, Chae S-W, Go YY, et al. In vitro Multi-Species Biofilms of Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa and Their Host Interaction During in vivo Colonization of an Otitis Media Rat Model. Front Cell Infect Microbiol. 2017;7:125.
[256] Jeon E-J, Park Y-S, Lee SK, et al. Effect of nitric oxide and peroxynitrite on mucociliary transport function of experimental otitis media. Otolaryngol Head Neck Surg. 2006;134(1):126–131.
[257] Schousboe LP, Ovesen T, Eckhardt L, et al. How does endotoxin trigger inflammation in otitis media with effusion? The Laryngoscope. 2001;111(2):297–300.
[258] Zielnik-Jurkiewicz B, Stankiewicz-Szymczak W. Pro-inflammatory interleukins in middle ear effusions from atomic and non-atopic children with chronic otitis media with effusion. Eur Arch Otorhinolaryngol. 2016;273(6):1369–1378.
[259] MacArthur CJ, Helfeneider SH, Kempton JB, et al. C3H/HeJ mouse model for spontaneous chronic otitis media. The Laryngoscope. 2006;116(7):1071–1079.
[260] Jotic A, Jesic S, Zivkovic M, et al. Polymorphisms in Toll-like receptors 2 and 4 genes and their expression in chronic suppurative otitis media. Auris Nasus Larynx. 2015;42(6):431–437.
[261] Si Y, Zhang ZG, Chen SJ, et al. Attenuated TLRs in middle ear mucosa contributes to susceptibility of chronic suppurative otitis media. Hum Immunol. 2014;75(8):771–776.
[262] Nason R, Lee DH, Jung JY, et al. Radiographic and Micro—Computed Tomographic Imaging of Lipopolysaccharide-Mediated Bone Resorption. Ann Otol Rhinol Laryngol. 2009;118(S):391–396.
[263] Mittal R, Grati M, Yan D, et al. Pseudomonas aeruginosa Activates PKC-Alpha to Invade Middle Ear Epithelial Cells. Front Microbiol. 2016;7:255.
[264] Mun JJ, Tam C, Kowbel D, et al. Clearance of Pseudomonas aeruginosa from a healthy ocular surface involves surfactant protein D and is compromised by bacterial elastase in a murine null-infection model. Infect Immun. 2009;77(6):2392–2398.
[265] Augustin DK, Heimer SR, Tam C, et al. Role of Defensins in Corneal Epithelial Barrier Function against Pseudomonas aeruginosa. Traversal. Infect Immun. 2011;79(2):595–605.
[266] Tam C, LeDue J, Mun JJ, et al. 3D quantitative imaging of unprocessed live tissue reveals epithelial defense against bacterial adhesion and subsequent traversal requires MyD88. PLoS One. 2011;6(8):e24008.
[267] Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea. 2008;27(1):22–27.
[268] Galentine PG, Cohen EJ, Laibson PR, et al. Corneal ulcers associated with contact lens wear. Arch Ophthalmol. 1984;102(6):891–894.
[269] Sy A, Srinivasan M, Mascarrenhas J, et al. Pseudomonas aeruginosa Keratitis: outcomes and Response to Corticosteroid Treatment. Invest Ophthalmol Vis Sci. 2012;53(1):267–272.
[270] Bharathi MJ, Ramakrishnan R, Shivakumar C, et al. Etiology and antibacterial susceptibility pattern of community-acquired bacterial ocular infections in a tertiary eye care hospital in south India. Indian J Ophthalmol. 2010;58(6):497–507.
[271] Yilmaz S, Ozturk I, Maden A. Microbial keratitis in West Anatolia, Turkey: a retrospective review. Int Ophthalmol. 2007;27(4):261–268.
[272] Fleisch SJ, Kroken AR, Nieto V, et al. Contact lens-related corneal infection: intrinsic resistance and its compromise. Prog Retin Eye Res. 2020;76:100804.
[273] Preston MJ, Fleischig SM, Zaidi TS, et al. Rapid and sensitive method for evaluating Pseudomonas aeruginosa virulence factors during corneal infections in mice. Infect Immun. 1995;63(9):3497–3501.

[274] Toska J, Sun Y, Carbonell DA, et al. Diversity of virulence phenotypes among type III secretion negative Pseudomonas aeruginosa clinical isolates. PLoS One. 2014;9(1):e86829.

[275] Zolfaghar I, Angus AA, Kang PJ, et al. Mutation of retS, encoding a putative hybrid two-component regulatory protein in Pseudomonas aeruginosa, attenuates multiple virulence mechanisms. Microbes Infect. 2005;7(13):1305–1316.

[276] Metruccio MME, Wan SJ, Horneman H, et al. A novel murine model for contact lens wear reveals clandestine IL-1R dependent corneal parainflammation and susceptibility to microbial keratitis upon inoculation with Pseudomonas aeruginosa. Ocul Surf. 2019;17(1):119–133.

[277] Zaidi TS, Lyczak J, Preston M, et al. Cystic Fibrosis Transmembrane Conductance Regulator-Mediated Corneal Epithelial Cell Ingestion of Pseudomonas aeruginosae a Key Component in the Pathogenesis of Experimental Murine Keratitis. Infect Immun. 1999;67(3):1481–1492.

[278] Zaidi T, Bajmoczi M, Zaidi T, et al. Disruption of CFTR-Dependent Lipid Rafts Reduces Bacterial Levels and Corneal Disease in a Murine Model of Pseudomonas aeruginosa Keratitis. Invest Ophthalmol Vis Sci. 2008;49(3):1000–1009.

[279] Fletcher EL, Fleischig SM, Brennan NA. Lipopolysaccharide in adherence of Pseudomonas aeruginosa to the cornea and contact lenses. Invest Ophthalmol Vis Sci. 1993;34(6):1930–1936.

[280] Evans D, Kuo T, Kwong M, et al. Pseudomonas aeruginosa strains with lipopolysaccharide defects exhibit reduced intracellular viability after invasion of corneal epithelial cells. Exp Eye Res. 2002;75(6):635–643.

[281] Kierbel A, Gassama-Diagne A, Rocha C, et al. Pseudomonas aeruginosa exploits a PIP3-dependent pathway to transform apical into basolateral membrane. J Cell Biol. 2007;177(1):21–27.

[282] Fletcher EL, Weissman BA, Efron N, et al. The role of pili in the attachment of Pseudomonas aeruginosa to unworn hydrogel contact lenses. Curr Eye Res. 1993;12(12):1067–1071.

[283] Hazlett LD, Zucker M, Berk RS. Distribution and kinetics of the inflammatory cell response to ocular challenge with Pseudomonas aeruginosa in susceptible versus resistant mice. Ophthalmic Res. 1992;24(1):32–39.

[284] Rudner XL, Zheng Z, Berk RS, et al. Corneal epithelial glycoproteins exhibit Pseudomonas aeruginosa pilus binding activity. Invest Ophthalmol Vis Sci. 1992;33(7):2185–2193.

[285] Fleischig SM, The Glenn A. Fry award lecture 2005. The pathogenesis of contact lens-related keratitis. Optom Vis Sci. 2006;83:866–873.

[286] Alarcon I, Evans DJ, Fleischig SMJ. The Role of Twitching Motility in Pseudomonas aeruginosa Exit from and Translocation of Corneal Epithelial Cells. Invest Ophthalmol Vis Sci. 2009;50(5):2237–2244.

[287] Nieto V, Kroken AR, Grosser MR, et al. Type IV Pili Can Mediate Bacterial Motility within Epithelial Cells. mBio. 2019;10(4):e02880–18.

[288] Robertson DM, Rogers NA, Petroll WM, et al. Second harmonic generation imaging of corneal stroma after infection by Pseudomonas aeruginosa. Sci Rep. 2017;7(1):46116.

[289] Fleischig SMJ, Arora SK, Van R, et al. FlH, a component of the flagellum assembly apparatus of Pseudomonas aeruginosa, plays a role in internalization by corneal epithelial cells. Infect Immun. 2001;69(8):4931–4937.

[290] Kroken AR, Chen CK, Evans DJ, et al. The Impact of ExoS on Pseudomonas aeruginosa Internalization by Epithelial Cells Is Independent of fleQ and Correlates with Bistability of Type Three Secretion System Gene Expression. mBio. 2018;9(3):e00668–18.

[291] Fleischig SM, Wiener-Kronish JP, Miyazaki H, et al. Pseudomonas aeruginosamediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. Infect Immun. 1997;65(2):579–586.

[292] Loumbolt JA, Poulsen K, Kilian M. Epidemic population structure of Pseudomonas aeruginosa: evidence for a clone that is pathogenic to the eye and that has a distinct combination of virulence factors. Infect Immun. 2001;69(10):6284–6295.

[293] Lakki C, Fleischig SM. Resistance of Pseudomonas aeruginosa isolates to hydrogel contact lens disinfection correlates with cytotoxic activity. J Clin Microbiol. 2001;39(4):1477–1486.

[294] Zhu H, Conibear TCR, Bandara R, et al. Type III Secretion System–Associated Toxins, Proteases, Serotypes, and Antibiotic Resistance of Pseudomonas aeruginosaisolates Associated with Keratitis. Curr Eye Res. 2006;31(4):297–306.

[295] Borkar DS, Acharya NR, Leong C, et al. Cytotoxic clinical isolates of Pseudomonas aeruginosaidentified during the Steroids for Corneal Ulcers Trial show elevated resistance to fluoroquinolones. BMC Ophthalmology. 2014;14(1):54.

[296] Cowell BA, Chen DY, Frank DW, et al. ExoT of Cytotoxic Pseudomonas aeruginosa Prevents Uptake by Corneal Epithelial Cells. Infect Immun. 2000;68(1):403–406.

[297] Cowell BA, Evans DJ, Fleischig SMJ. Actin cytoskeleton disruption by ExoY and its effects on Pseudomonas aeruginosainvasion. FEMS Microbiol Lett. 2005;250(1):71–76.

[298] Sun Y, Karmakar M, Taylor PR, et al. ExoS and ExoT ADP Ribosyltransferase Activities Mediate Pseudomonas aeruginosa Keratitis by Promoting Neutrophil Apoptosis and Bacterial Survival. J Immunol. 2012;188(4):1884–1895.

[299] Vareechon C, Zmina SE, Karmakar M, et al. Pseudomonas aeruginosae Effector ExoS Inhibits ROS Production in Human Neutrophils. Cell Host Microbe. 2017;21(5):611–8 65.

[300] Fleischig SM, Zaidi TS, Preston MJ, et al. Relationship between cytotoxicity and corneal epithelial cell invasion by clinical isolates of Pseudomonas aeruginosa. Infect Immun. 1996;64(6):2288–2294.
[301] Tam C, Lewis SE, Li WY, et al. Mutation of the phospholipase catalytic domain of the Pseudomonas aeruginosa cytotoxin ExoU abolishes colonization promoting activity and reduces corneal disease severity. Exp Eye Res. 2007;85(6):799–805.

[302] Ramirez JC, Fleischig SMJ, Sullivan AB, et al. Traversal of Multilayered Corneal Epithelia by Cytotoxic Pseudomonas aeruginosa Requires the Phospholipase Domain of ExoU. Invest Ophthalmol Vis Sci. 2012;53(1):448–453.

[303] Zolfaghari I, Evans DJ, Ronaghi M, et al. Type III secretion-dependent modulation of innate immunity as one of multiple factors regulated by Pseudomonas aeruginosa ReTS. Infect Immun. 2006;74(7):3880–3889.

[304] Twining SS, Kirschner SE, Mahnke LA, Frank DW, Twining SS, Kirschner SE, Mahnke LA. Effect of Pseudomonas aeruginosa elastase, alkaline protease, and exotoxin A on corneal proteinases and proteins. Invest Ophthalmol Vis Sci. 1993;34(9):2699–2712.

[305] Marquart ME, Dajcs JI, Caballero AR, et al. Calcium and magnesium enhance the production of Pseudomonas aeruginosa protease IV, a corneal virulence factor. Med Microbiol Immunol. 2005;194(1–2):39–45.

[306] Kreger AS, Gray LD. Purification of Pseudomonas aeruginosa proteases and microscopic characterization of pseudomonal protease-induced rabbit corneal damage. Infect Immun. 1978;19(2):630–648.

[307] Ijiri Y, Yamamoto T, Kamata R, et al. The role of Pseudomonas aeruginosa elastase in corneal ring abscess formation in pseudomonal keratitis. Graefes Arch Clin Exp Ophthalmol. 1993;231(9):521–528.

[308] Marquart ME, Caballero AR, Chomnawang M, Marquart ME, Caballero AR, Chomnawang M, Thibodeaux BA, Twining SS, O’Callaghan RJ. Identification of a Novel Secreted Protease from Pseudomonas aeruginosa that Causes Corneal Erosions. Invest Ophthalmol Vis Sci. 2005;46(10):3761–3768.

[309] Engel LS, Hill JM, Moreau JM, et al. Pseudomonas aeruginosa protease IV produces corneal damage and contributes to bacterial virulence. Invest Ophthalmol Vis Sci. 1998;39(3):662–665.

[310] Tang A, Marquart ME, Fratkin JD, et al. Properties of PASP: a Pseudomonas Protease Capable of Mediating Corneal Erosions. Invest Ophthalmol Vis Sci. 2009;50(8):3794–3801.

[311] Mochizuki Y, Suzuki T, Oka N, et al. Pseudomonas aeruginosa MucD Protease Mediates Keratitis by Inhibiting Neutrophil Recruitment and Promoting Bacterial Survival. Invest Ophthalmol Vis Sci. 2014;55(1):240–246.

[312] White CD, Alionte LG, Cannon BM, et al. Corneal Virulence of LaA Protease-deficient Pseudomonas aeruginosa PA01. Cornea. 2001;20(6):643–646.

[313] Azghani AO. Pseudomonas aeruginosa and epithelial permeability: role of virulence factors elastase and exotoxin A. Am J Respir Cell Mol Biol. 1996;15(1):132–140.

[314] Iglewski BH, Burns RP, Gipson IK. Pathogenesis of corneal damage from Pseudomonas exotoxin A. Invest Ophthalmol Vis Sci. 1997;16(1):73–76.

[315] Pillar CM, Hobden JA. Pseudomonas aeruginosa exotoxin A and keratitis in mice. Invest Ophthalmol Vis Sci. 2002;43(5):1437–1444.

[316] Tam C, Mun JJ, Evans DJ, et al. The Impact of Inoculation Parameters on the Pathogenesis of Contact Lens–Related Infectious Keratitis. Invest Ophthalmol Vis Sci. 2010;51(6):3100–3106.

[317] Wu YT-Y, Willcox M, Zhu H, et al. Contact lens hygiene compliance and lens case contamination: a review. Cont Lens Anterior Eye. 2015;38(5):307–316.

[318] Ha D-G, O’Toole GA. c-di-GMP and its Effects on Biofilm Formation and Dispersion: a Pseudomonas aeruginosa Review. Microbiol Spectr. 2015;3(2):MB-0003-2014.

[319] Hickman JW, Harwood CS. Identification of FleQ from Pseudomonas aeruginosa as a c-di-GMP-responsive transcription factor. Mol Microbiol. 2008;69(2):376–389.

[320] Lamont IL, Beare PA, Ochsner U, et al. Siderophore-mediated signaling regulates virulence factor production in Pseudomonas aeruginosa. Proc Natl Acad Sci U S A. 2002;99(10):7072–7077.

[321] Suzuki T, Okamoto S, Oka N, et al. Role of pvdE Pyoverdine Synthesis in Pseudomonas aeruginosa Keratitis. Cornea. 2018;37(Suppl 1):S99–S105.

[322] St Sauver JL, Warner DO, Yawn BP, et al. Why Patients Visit Their Doctors: assessing the Most Prevalent Conditions in a Defined American Population. Mayo Clin Proc. 2013;88(1):56–67.

[323] Maradit Kremers H, Larson DR, Crowson CS, et al. Prevalence of Total Hip and Knee Replacement in the United States. J Bone Joint Surg. 2015;97(17):1386–1397.

[324] Fehring TK, Odum SM, Troyer JL, et al. Joint Replacement Access in 2016: a Supply Side Crisis. J Arthroplasty. 2010;25(8):1175–1181.

[325] Kurtz S, Ong K, Lau E, et al. Projections of Primary and Revision Hip and Knee Arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg. 2007;89(4):780–785.

[326] Kurtz SM, Ong KL, Lau E, et al. Prosthetic joint infection risk after TKA in the Medicare population. Clin Orthop Relat Res. 2010;468(1):52–56.

[327] Ong KL, Kurtz SM, Lau E, et al. Prosthetic joint infection risk after total hip arthroplasty in the Medicare population. J Arthroplasty. 2009;24(6):105–109.

[328] Nowicki B, Runyan RS, Smith N, et al. Kinetics of colonization of a porous vitreous carbon percutaneous implant. Biomaterials. 1990;11(6):389–392.

[329] Pendegrass CJ, Goodship AE, Price JS, et al. Nature’s answer to breaching the skin barrier: an innovative development for amputees. J Anat. 2006;209(1):59–67.

[330] Juhnke D-L, Beck JP, Jeyapalina S, et al. Fifteen years of experience with Integral-Leg-Prosthesis: cohort study of artificial limb attachment system. J Rehabil Res Dev. 2015;52(4):407–420.

[331] Kingscott P, Wei J, Bagge-Ravn D, et al. Covalent Attachment of Poly(ethylene glycol) to Surfaces, Critical for Reducing Bacterial Adhesion. Langmuir. 2003;19(17):6912–6921.

[332] Neoh KG, Kang ET. Combating Bacterial Colonization on Metals via Polymer Coatings: relevance to Marine
and Medical Applications. ACS Appl Mater Interfaces. 2011;3(8):2808–2819.

[333] Zilberman M, Elsner JJ. Antibiotic-eluting medical devices for various applications. J Control Release. 2008;130(3):202–215.

[334] Hetrick EM, Schoenfisch MH. Reducing implant-related infections: active release strategies. Chem Soc Rev. 2006;35(9):780–789.

[335] Fuchs T, Stange R, Schmidmaier G, et al. The use of gentamicin-coated nails in the tibia: preliminary results of a prospective study. Arch Orthop Trauma Surg. 2011;131(10):1419–1425.

[336] Williams DL, Lerdahl JM, Haymond BS, et al. In Vitro Efficacy of a Novel Active-Release Antimicrobial Coating To Eradicate Biofilms of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2014;58(4):2400–2404.

[337] Shin Y, Akao M. Tissue Reactions to Various Percutaneous Materials with Different Surface Properties and Structures. Artif Organs. 2008;21(9):995–1001.

[338] Chou TGR, Petti CA, Szakacs J, et al. Evaluating antimicrobials and implant materials for infection prevention around transcutaneous osseointegrated implants in a rabbit model. J Biomed Mater Res A. 2010;92A:942–952.

[339] Allyn G, Bloebaum RD, Epperson RT, et al. Ability of a wash regimen to remove biofilm from the exposed surface of materials used in osseointegrated implants. J Orthop Res. 2019;37(1):248–257.

[340] Neu HC. The Crisis in Antibiotic Resistance. Science. 1992;257(5073):1064–1073.

[341] Fernández L, Breidenstein EBM, Hancock REW. Creeping baselines and adaptive resistance to antibiotics. Drug Resist Updat. 2011;14:1–21.

[342] Campoccia D, Montanaro L, Speziale P, et al. Antibiotic-loaded biomaterials and the risks for the spread of antibiotic resistance following their prophylactic and therapeutic clinical use. Biomaterials. 2010;31(25):6363–6377.

[343] Bränenmark RP, Hagberg K, Kulbacka-Ortiz K, et al. Osseointegrated Percutaneous Prosthetic System for the Treatment of Patients With Transfemoral Amputation: a Prospective Five-year Follow-up of Patient-reported Outcomes and Complications. J Am Acad Orthop Surg. 2019;27(16):e743–e51.

[344] Atlallah R, Leijendekkers RA, Hoogeboom TJ, et al. Complications of bone-anchored prostheses for individuals with an extremity amputation: a systematic review. Plos One. 2018;13(8):e0201821.

[345] Overmann AL, Aparicio C, Richards JT, et al. Orthopaedic osseointegration: implantology and future directions. J Orthop Res. 2020;38(7):1445–1454.

[346] Andonian S, Rabah DM, Aprikian AG. Pseudomonas aeruginosa sacroiliitis and osteomyelitis of pelvic bones after radical prostatectomy. Urology. 2002;60(4):698.

[347] Hartemann-Heurtier A, Senneville E. Diabetic foot osteomyelitis. Diabetes & Metabolism. 2008;34(2):87–95.

[348] Arciola CR, An YH, Campoccia D, et al. Etiology of implant orthopedic infections: a survey on 1027 clinical isolates. Int J Artif Organs. 2005;28(11):1091–1100.

[349] Masters EA, Trombetta RP, De Mesy Bentley KL, et al. Evolving concepts in bone infection: redefining “biofilm”, “acute vs. chronic osteomyelitis”, “the immune proteome” and “local antibiotic therapy”. Bone Research. 2019;7(1). DOI:10.1088/441413-019-0061-z.

[350] Blyth CC, Gomes L, Sorrell TC, et al. Skull-base osteomyelitis: fungal vs. bacterial infection. Clinical Microbiology and Infection. 2011;17(2):306–311.

[351] Parvizi J, Azzam K, Ghanem E, et al. Periprosthetic infection due to resistant staphylococci: serious problems on the horizon. Clin Orthop Relat Res. 2009;467(7):1732–1739.

[352] Carrega G, Bartolacci V, Burastero G, et al. Etiology of prosthetic joint infections in a tertiary care centre in Italy. Infez Med. 2008;16(4):204–208.

[353] Zmistowski B, Fedorka CJ, Sheehan E, et al. Prosthetic joint infection caused by gram-negative organisms. J Arthroplasty. 2011;26(6):104–108.

[354] Hsieh P-H, Lee MS, Hsu K-Y, et al. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis. 2009;49(7):1036–1043.

[355] Wegner AM, Wuellner JC, Haus BM. Pseudomonas aeruginosa Septic Arthritis and Osteomyelitis after Closed Reduction and Percutaneous Pinning of a Supracondylar Humerus Fracture: a Case Report and Review of the Literature. Case Rep Orthop 2017;2017:8721835.

[356] Smith JW, Chalupa P, Shabaz Hasan M. Infectious arthritis: clinical features, laboratory findings and treatment. Clin Microbiol Infect. 2006;12(4):309–314.

[357] Goldenberg DL, Brandt KD, Cathcart ES, et al. Acute arthritis caused by gram-negative bacilli: a clinical characterization. Medicine (Baltimore). 1974;53(3):197–208.

[358] Thompson JM, Miller RJ, Ashbaugh AG, et al. Mouse model of Gram-negative prosthetic joint infection reveals therapeutic targets. JCI Insight. 2018;3(17):e121737.

[359] Mahmood F, Hakimiyan A, Jayaraman V, et al. A novel human antimicrobial factor targets Pseudomonas aeruginosa through its type III secretion system. J Med Microbiol. 2013;62(4):531–539.

[360] Jin T, Mohammad M, Hu Z, et al. A novel mouse model for septic arthritis induced by Pseudomonas aeruginosa. Sci Rep. 2019;9(1):16868.

[361] Marshall JC, Christou NV, Meakins JL. The gastrointestinal tract. The “undrained abscess” of multiple organ failure. Ann Surg. 1993;218:111–119.

[362] Falcao DP, Mendonca CP, Scrasolo A, et al. Nursery outbreak of severe diarrhoea due to multiple strains of Pseudomonas aeruginosa. Lancet. 1972;300(7766):38–40.

[363] Florman AL, Schifrin N. Observations on a small outbreak of infantile diarrhoea associated with Pseudomonas aeruginosa. J Pediatr. 1950;36(6):758–766.

[364] Chung C-H, Janapatla RP, Wang Y-H, et al. Pseudomonas aeruginosa-associated Diarrheal Diseases in Children. Pediatr Infect Dis J. 2017;36(12):1119–1123.
[365] Adlard PA, Kirov SM, Sanderson K, et al. Pseudomonas aeruginosa as a cause of infectious diarrhoea. Epidemiol Infect. 1998;121(1):237–241.

[366] Kim SW, Peck KR, Jung SI, et al. Pseudomonas aeruginosa as a Potential Cause of Antibiotic-Associated Diarrhea. J Korean Med Sci. 2001;16(6):742–744.

[367] Nelson RK, Poroyko V, Morowitz MJ, et al. Effect of Dietary Monosaccharides on Pseudomonas aeruginosa Virulence. Surg Infect (Larchmt). 2013;14(1):35–42.

[368] Chuang C-H, Wang Y-H, Chang H-J, et al. Shanghai fever: a distinct Pseudomonas aeruginosa enteric disease. Gut. 2014;63(5):736–743.

[369] Herve RC. Endoscopy in the twenty-first century: minimally invasive state-of-the-art medical technology or a future main vector of hospital-acquired infections? J Hosp Infect. 2017;97(4):329–330.

[370] Chen C-Y, Chen Y-C, Pu H-N, et al. Bacteriology of acute appendicitis and its implication for the use of prophylactic antibiotics. Surg Infect (Larchmt). 2012;13(6):383–390.

[371] Andrey V, Crisinel P-A, Prod’hom G, et al. Impact of co-amoxicillin-resistant Escherichia coli and Pseudomonas aeruginosa on the rate of infectious complications in paediatric complicated appendicitis. Swiss Med Wkly. 2019;149:w20055.

[372] Chan EYH, Borzych-Duzalka D, Alparslan C, et al. Colostomy in children on chronic peritoneal dialysis. Pediatr Nephrol. 2020;35(1):119–126.

[373] Vikstrom E, Tafazoli F, Magnusson K-E. Pseudomonas aeruginosa quorum sensing molecule N-(3-oxododecanoyl)-l-homoserine lactone disrupts epithelial barrier integrity of Caco-2 cells. FEBS Lett. 2006;580(30):6921–6928.

[374] Vikstrom E, Bui L, Konradsson P, et al. Role of calcium signallling and phosphorylations in disruption of the epithelial junctions by Pseudomonas aeruginosa quorum sensing molecule. Eur J Cell Biol. 2010;89(8):584–597.

[375] Karlsson T, Turkina MV, Yakymenko O, et al. The Pseudomonas aeruginosa N-acylhomoserine lactone quorum sensing molecules target IQGAP1 and modulate epithelial cell migration. PLoS Pathog. 2012;8(10):e1002953.

[376] Coquant G, Grill J-P, Seksik P. Impact of N-Acyl-Homoserine Lactones, Quorum Sensing Molecules, on Gut Immunity. Front Immunol. 2020;11:1827.

[377] Laughlin RS, Musch MW, Hollbrook CJ, et al. The key role of Pseudomonas aeruginosa PA-I lectin on experimental gut-derived sepsis. Ann Surg. 2000;232(1):133–142.

[378] Alverdy J, Hollbrook C, Rocha F, et al. Gut-derived sepsis occurs when the right pathogen with the right virulence genes meets the right host: evidence for in vivo virulence expression in Pseudomonas aeruginosa. Ann Surg. 2000;232(4):480–489.

[379] Zaborin A, Gerdes S, Hollbrook C, et al. Pseudomonas aeruginosa overrides the virulence inducing effect of opioids when it senses an abundance of phosphate. PLoS One. 2012;7(4):e34883.

[380] Hayashi N, Nishizawa H, Kitao S, et al. Pseudomonas aeruginosa injects type III effector ExoS into epithelial cells through the function of type IV pili. FEBS Lett. 2015;589(8):890–896.

[381] Okuda J, Hayashi N, Okamoto M, et al. Translocation of Pseudomonas aeruginosa from the intestinal tract is mediated by the binding of ExoS to an Na,K-ATPase regulator, FXYD3. Infect Immun. 2010;78(11):4511–4522.

[382] Okuda J, Okamoto M, Hayashi N, et al. Complementation of the exoS gene in the pdvE pyoverdine synthesis gene-deficient mutant of Pseudomonas aeruginosa results in recovery of the pdvE gene-mediated penetration through the intestinal epithelial cell barrier but not the pdvE-mediated virulence in silkworms. J Infect Chemother. 2012;18(3):332–340.

[383] Skurnik D, Roux D, Aschard H, et al. A comprehensive analysis of in vitro and in vivo genetic fitness of Pseudomonas aeruginosa using high-throughput sequencing of transposon libraries. PLoS Pathog. 2013;9(9):e1003582.

[384] Koh AY, Mikkelsen PJ, Smith RS, et al. Utility of in vivo transcription profiling for identifying Pseudomonas aeruginosa genes needed for gastrointestinal colonization and dissemination. PLoS One. 2010;5(12):e15131.

[385] Wheeler KM, Carcamo-Oyarce G, Turner BS, et al. Mucin glycans attenuate the virulence of Pseudomonas aeruginosa in infection. Nat Microbiol. 2019;4(12):2146–2154.

[386] Hofman CL, Lalsiamthara A, Aballay A. Host Mucin Is Exploited by Pseudomonas aeruginosa To Provide Monosaccharides Required for a Successful Infection. mBio. 2020;11(2):e00600–20.

[387] Newman JW, Floyd RV, Fothergill JL. The contribution of Pseudomonas aeruginosa virulence factors and host factors in the establishment of urinary tract infections. FEMS Microbiol Lett. 2017;364(15):364.

[388] Mittal R, Aggarwal S, Sharma S, et al. Urinary tract infections caused by Pseudomonas aeruginosa: a minireview. J Infect Public Health. 2009;2(3):101–111.

[389] Olejnickova K, Hola V, Ruzicka F. Catheter-related infections caused by Pseudomonas aeruginosa: virulence factors involved and their relationships. Pathog Dis. 2014;72(2):87–94.

[390] Tielen P, Narten M, Rosin N, et al. Genotypic and phenotypic characterization of Pseudomonas aeruginosa isolates from urinary tract infections. Int J Med Microbiol. 2011;301(4):282–292.

[391] Cole SJ, Records AR, Orr MW, et al. Catheter-associated urinary tract infection by Pseudomonas aeruginosa is mediated by exopolysaccharide-independent biofilms. Infect Immun. 2014;82(5):2048–2058.

[392] Pedersen SS. Lung infection with alginic-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis. APMIS Suppl. 1992;28:1–79.

[393] Tielen P, Rosin N, Meyer A-K, et al. Regulatory and metabolic networks for the adaptation of Pseudomonas aeruginosa biofilms to urinary tract-like conditions. PLoS One. 2013;8(8):e71845.

[394] Gupta RK, Harjai K, Chhibber S. Rhq quorum sensing affects the virulence potential of Pseudomonas aeruginosa in an experimental urinary tract infection. Antonie Van Leeuwenhoek. 2016;109(12):1535–1544.
[395] Kumar R, Chhibber S, Harjai K. Quorum sensing is necessary for the virulence of *Pseudomonas aeruginosa* during urinary tract infection. Kidney Int. 2009;76 (3):286–292.

[396] Bala A, Chhibber S, Harjai K. *Pseudomonas* quinolone signalling system: a component of quorum sensing cascade is a crucial player in the acute urinary tract infection caused by *Pseudomonas aeruginosa*. Int J Med Microbiol. 2014;304(8):1199–1208.

[397] Cole SJ, Hall CL, Schniederberend M, et al. Host suppression of quorum sensing during catheter-associated urinary tract infections. Nat Commun. 2018;9(1):4436.

[398] Shand GH, Anwar H, Kadurugamuwa J, et al. In vivo evidence that bacteria in urinary tract infection grow under iron-restricted conditions. Infect Immun. 1985;48(1):35–39.

[399] Visca P, Chiarini F, Mansi A, et al. Virulence determinants in *Pseudomonas aeruginosa* strains from urinary tract infections. Epidemiol Infect. 1992;108 (2):323–336.

[400] Wolz C, Hohloch K, Ocaktan A, et al. Iron release from transferrin by pyoverdin and elastase from *Pseudomonas aeruginosa*. Infect Immun. 1994;62 (9):4021–4027.

[401] Mittal R, Khandwaha RK, Gupta V, et al. Phenotypic characters of urinary isolates of *Pseudomonas aeruginosa* & their association with mouse renal colonization. Indian J Med Res. 2006;123(1):67–72.

[402] Woods DE, Schaffer MS, Rabin HR, et al. Phenotypic comparison of *Pseudomonas aeruginosa* strains isolated from a variety of clinical sites. J Clin Microbiol. 1986;24(2):260–264.

[403] Hamood AN, Griswold JA, Duhan CM. Production of Extracellular Virulence Factors by *Pseudomonas aeruginosa* isolates Obtained from Tracheal, Urinary Tract, and Wound Infections. J Surg Res. 1996;61 (2):425–432.

[404] Mossine VV, Waters JK, Chance DL, et al. Transient Proteotoxicity of Bacterial Virulence Factor Pyocyanin in Renal Tubular Epithelial Cells Induces ER-Related Vacuolation and Can Be Efficiently Modulated by Iron Chelators. Toxicol Sci. 2016;154(2):403–415.

[405] Magill SS, Edwards JR, Bamberg W, et al. Multistate Point-Prevalence Survey of Health Care–Associated Infections. N Engl J Med. 2014;370(13):1198–1208.

[406] Thaden JT, Park LP, Maskarinec SA, et al. Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by *Pseudomonas aeruginosa* Compared to Other Bacteria. Antimicrob Agents Chemother. 2017;61(6):e02671–16.

[407] Veve MP, McCurry ED, Cooksey GE, et al. Epidemiology and outcomes of non-HACEK infective endocarditis in the southeast United States. PLoS One. 2020;15(3):e0230199.

[408] Dawson NL, Brumble LM, Pritt BS, et al. Left-sided *Pseudomonas aeruginosa* endocarditis in patients without injection drug use. Medicine (Baltimore). 2011;90 (4):250–255.

[409] Yoon E-J, Kim D, Lee H, et al. Mortality dynamics of *Pseudomonas aeruginosa* bloodstream infections and the influence of defective OprD on mortality: prospective observational study. J Antimicrob Chemother. 2019;74(9):2774–2783.

[410] Shi Q, Huang C, Xiao T, et al. A retrospective analysis of *Pseudomonas aeruginosa* bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and -non-susceptible infections. Antimicrob Resist Infect Control. 2019;8(1):68.

[411] Mickel ST, Lloyd AE, Ritchie DJ, et al. *Pseudomonas aeruginosa* bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005;49(4):1306–1311.

[412] McCarthy KL, Wailan AM, Jennison AV, et al. *P. aeruginosa* blood stream infection isolates: a “full house” of virulence genes in isolates associated with rapid patient death and patient survival. Microb Pathog. 2018;119:81–85.

[413] Hickey C, Schaille B, Nguyen S, Hurley D, Srikumar S, Fanning S, et al. Increased Virulence of Bloodstream Over Peripheral Isolates of *P. aeruginosa* Identified Through Post-transcriptional Regulation of Virulence Factors. Front Cell Infect Microbiol. 2018;8:357.

[414] Harrison EM, Carter M, Luck S, et al. Pathogenicity islands PAPI-1 and PAPI-2 contribute individually and synergistically to the virulence of *Pseudomonas aeruginosa* strain PA14. Infect Immun. 2018;78 (4):1437–1446.

[415] Peña C, Cabot G, Gómez-Zorrilla S, et al. Influence of virulence genotype and resistance profile in the mortality of *Pseudomonas aeruginosa* bloodstream infections. Clin Infect Dis. 2015;60(4):539–548.

[416] Finck-Barbançon V, Goranson J, Zhu L, et al. ExoU expression by *Pseudomonas aeruginosa* correlates with acute cytotoxicity and epithelial injury. Mol Microbiol. 1997;25(3):547–557.

[417] Javanmardi F, Emami A, Pirbonyeh N, et al. A systematic review and meta-analysis on Exo-toxins prevalence in hospital acquired *Pseudomonas aeruginosa* isolates. Infect Genet Evol. 2019;75:104037.

[418] Sato H, Frank DW, Hillard CJ, et al. The mechanism of action of the *Pseudomonas aeruginosa*-encoded type III cytotoxin, ExoU. EMBO J. 2003;22(12):2959–2969.

[419] Berube BJ, Rangel SM, Hauser AR. *Pseudomonas aeruginosa*: breaking down barriers. Curr Genet. 2016;62 (1):109–113.

[420] Bayer AS, Park S, Ramos MC, et al. Effects of alginate on the natural history and antibiotic therapy of experimental endocarditis caused by mucoid *Pseudomonas aeruginosa*. Infect Immun. 1992;60(10):3979–3985.

[421] Xiong Y-Q, Vasil ML, Johnson Z, et al. The Oxygen- and Iron-Dependent Sigma Factor pvdS of *Pseudomonas aeruginosa* Is an Important Virulence Factor in Experimental Infective Endocarditis. J Infect Dis. 2000;181(3):1020–1026.

[422] Pai S, Bedford L, Ruramayi R, et al. *Pseudomonas aeruginosa* meningitis/ventriculitis in a UK tertiary referral hospital. QJM. 2016;109(2):85–89.

[423] Balcron R, Pittert J-F, Wagener BM, et al. Infection-induced endothelial amyloids impair memory. FASEB J. 2019;33(9):10300–10314.

[424] Tapiola T, Alafuzzo I, Herukka S-K, et al. Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins
as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain. Arch Neurol. 2009;66(3):382–389.

[425] Yahrl TL, Vallis AJ, Hancock MK, et al. ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc Natl Acad Sci U S A. 1998;95(23):13899–13904.

[426] Carlyle BC, Nairn AC, Wang M, et al. cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex. Proc Natl Acad Sci U S A. 2014;111(13):5036–5041.

[427] Balczon R, Prasain N, Ochoa C, et al. Pseudomonas aeruginosa exotoxin Y-mediated tau hyperphosphorylation impairs microtubule assembly in pulmonary microvascular endothelial cells. PLoS One. 2013;8(9):e74343.

[428] Saliba AM, De Assis M-C, Nishi R, et al. Implications of oxidative stress in the cytotoxicity of Pseudomonas aeruginosa ExoU. Microbes Infect. 2006;8(2):450–459.

[429] King ME, Gamblin TC, Kuret J, King ME, Gamblin TC, Kuret J, Binder LI. Differential assembly of human tau isoforms in the presence of arachidonic acid. J Neurochem. 2000;74(4):1749–1757.

[430] Turner KH, Everett J, Trivedi U, et al. Requirements for Pseudomonas aeruginosa Acute Burn and Chronic Surgical Wound Infection. Plos Genetics. 2014;10(10):e1004743.

[431] Azzopardi EA, Azzopardi E, Camilleri L, et al. Gram Negative Wound Infection in Hospitalised Adult Burn Patients-Systematic Review and Metanalysis-. PLoS One. 2014;9(4):e95042.

[432] Brandenburg KS, Weaver AJ Jr., Karna SLR, et al. Formation of Pseudomonas aeruginosa Biofilms in Full-thickness Scald Burn Wounds in Rats. Sci Rep. 2019;9(1):13627.

[433] Rumbaugh KP, Griswold JA, Iglewski BH, et al. Contribution of Quorum Sensing to the Virulence of Pseudomonas aeruginosa in Burn Wound Infections. Infect Immun. 1999;67(11):5854–5862.

[434] Schaber JA, Triffo WJ, Suh SJ, et al. Pseudomonas aeruginosa forms biofilms in acute infection independent of cell-to-cell signaling. Infect Immun. 2007;75(8):3715–3721.

[435] Cox CD, Parker J. Use of 2-aminoacetophenone production in identification of Pseudomonas aeruginosa. J Clin Microbiol. 1979;9(4):479–484.

[436] Kesarwani M, Hazan R, He J, et al. A quorum sensing regulated small volatile molecule reduces acute cutaneous inflammation and promotes chronic infection phenotypes. PLoS Pathog. 2011;7(8):e1002192.

[437] Bandyopadhyaya A, Kesarwani M, Que YA, et al. The Quorum Sensing Volatile Molecule 2-Amino Acetophenon Modulates Host Immune Responses in a Manner that Promotes Life with Unwanted Guests. Plos Pathogens. 2012;8(11):e1003024.

[438] Kim M, Christley S, Khodarev NN, et al. Pseudomonas aeruginosa wound infection involves activation of its iron acquisition system in response to fascial contact. J Trauma Acute Care Surg. 2015;78(4):823–829.

[439] Muller M, Li Z, Maitz PKM. Pseudomonas pyocyanin inhibits wound repair by inducing premature cellular senescence: role for p38 mitogen-activated protein kinase. Burns. 2009;35(4):500–508.

[440] Sato H, Okinaga K, Saito H. Role of Pili in the Pathogenesis of Pseudomonas aeruginosa Burn Infection. Microbiol Immunol. 1988;32(2):131–139.

[441] Arora SK, Neely AN, Blair B, et al. Role of motility and flagellin glycosylation in the pathogenesis of Pseudomonas aeruginosa burn wound infections. Infect Immun. 2005;73(7):4395–4398.

[442] Garcia M, Morello E, Garnier J, et al. Pseudomonas aeruginosa flagellin is critical for invasion, cutaneous persistence and induction of inflammatory response of skin epidermis. Virulence. 2018;9(1):1163–1175.

[443] Kruzczek C, Kottapalli KR, Dissanaike S, et al. Major Transcriptome Changes Accompany the Growth of Pseudomonas aeruginosa in Blood from Patients with Severe Thermal Injuries. PLoS One. 2016;11(3):e0149229.

[444] Gonzalez MR, Ducret V, Leoni S, et al. Transcriptome Analysis of Pseudomonas aeruginosa Cultured in Human Burn Wound Exudates. Front Cell Infect Microbiol. 2018;8:39.

[445] Bjarnsholt T, Kirketerp-Møller K, Jensen PØ, et al. Why chronic wounds will not heal: a novel hypothesis. Wound Repair Regen. 2008;16(1):2–10.

[446] Zhao G, Hochwalt PC, Usui ML, et al. Delayed wound healing in diabetic (db/db) mice with Pseudomonas aeruginosa biofilm challenge: a model for the study of chronic wounds. Wound Repair Regen. 2010;18(5):467–477.

[447] Zhao G, Usui ML, Underwood RA, et al. Time course study of delayed wound healing in a biofilm-challenged diabetic mouse model. Wound Repair Regen. 2012;20(3):342–352.

[448] Prasad ASB, Shruptha P, Prabhu V, et al. Pseudomonas aeruginosa virulence proteins pseudolysin and protease IV impede cutaneous wound healing. Lab Invest. 2020;100(12):1532–1550.

[449] Jacobsen JN, Andersen AS, Krogfelt KA. Impact of Pseudomonas aeruginosa quorum sensing on cellular wound healing responses in vitro. Scand J Infect Dis. 2012;44(8):615–619.

[450] Goldusky J, Wood SJ, Jayaraman V, et al. Pseudomonas aeruginosa uses T3SS to inhibit diabetic wound healing. Wound Repair Regen. 2015;23(4):557–564.

[451] Jacobson JA. Pool-Associated Pseudomonas aeruginosa Dermatitis and Other Bathing-Associated Infections. Infection Control. 1985;6(10):398–401.

[452] Vaiman M, Lasarovitch T, Heller L, et al. Ecthyma gangrenosum versus ecthyma-like lesions: should we separate these conditions? Acta Dermato-venereolog Alp Pannonica Adriat. 2015;24(4):69–72.

[453] Maniatis AN, Karkavitsas C, Maniatis NA, et al. Pseudomonas aeruginosa folliculitis due to non-O:11 serogroups: acquisition through use of contaminated synthetic sponges. Clin Infect Dis. 1995;21(2):437–439.

[454] Highsmith AK, Le PN, Khabbaz RF, et al. Characteristics of Pseudomonas aeruginosa Isolated From Whirlpools and Bathers. Infection Control. 1985;6(10):407–412.
[455] Berrouane YF, McNutt L-A, Buschelman BJ, et al. Outbreak of Severe *Pseudomonas aeruginosa* Infections Caused by a Contaminated Drain in a Whirlpool Bathtub. Clin Infect Dis. 2000;31 (6):1331–1337.

[456] Faure K, Shimabukuro D, Ajayi T, et al. O-antigen serotypes and type III secretory toxins in clinical isolates of *Pseudomonas aeruginosa*. J Clin Microbiol. 2003;41(5):2158–2160.

[457] Stewart RMK, Wiehlmann L, Ashelford KE, et al. Genetic Characterization Indicates a Specific Subpopulation of *Pseudomonas aeruginosa* Is Associated with Keratitis Infections. J Clin Microbiol. 2011;49(3):993–1003.

[458] Berube BJ, Murphy KR, Torhan MC, et al. Impact of Type III Secretion Effectors and of Phenoxacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of *Pseudomonas aeruginosa* Infection. Antimicrob Agents Chemother. 2017;61 (11):e01202–17.

[459] Hebert F-O, Boyle B, Levesque RC. Direct In Vivo Microbial Transcriptomics During Infection. Trends Microbiol. 2018;26(9):732–735.

[460] Cornforth DM, Dees JL, Ibberon CB, et al. *Pseudomonas aeruginosa* transcriptome during human infection. Proc Natl Acad Sci U S A. 2018;115(22):E5125–E34.

[461] Ailloud F, Didelot X, Woltemate S, et al. Within-host evolution of Helicobacter pylori shaped by niche-specific adaptation, intragastric migrations and selective sweeps. Nat Commun. 2019;10(1):2273."

[462] Wang T, Zhang X, Liu Z, et al. Single-cell RNA sequencing reveals the sustained immune cell dysfunction in the pathogenesis of sepsis secondary to bacterial pneumonia. Genomics. 2021;113(3):1219–1233.

[463] Marti-Figuerora CR, Ashton RS. The case for applying tissue engineering methodologies to instruct human organoid morphogenesis. Acta Biomater. 2017;54:35–44.

[464] Vandamme TF. Use of rodents as models of human diseases. J Pharm Bioallied Sci. 2014;6(1):2–9.

[465] Ishida S. Organs-on-a-chip: current applications and consideration points for in vitro ADME-Tox studies. Drug Metab Pharmacokinet. 2018;33(1):49–54.

[466] Ji S, Guvendiren M. Recent Advances in Bioink Design for 3D Bioprinting of Tissues and Organs. Front Bioeng Biotechnol. 2017;5:23.

[467] Grigoryan B, Sazer DW, Avila A, et al. Development, characterization, and applications of multi-material stereolithography bioprinting. Sci Rep. 2021;11 (1):3171.

[468] Zheng F, Xiao Y, Liu H, et al. Patient-Specific Organoid and Organ-on-a-Chip: 3D Cell-Culture Meets 3D Printing and Numerical Simulation. Advanced Biology. 2021:e2000024. doi:10.1002/ adbi.202000024

[469] Mithal A, Hume AJ, Lindstrom-Vautrin J, et al. Human Pluripotent Stem Cell-Derived Intestinal Organoids Model SARS-CoV-2 Infection Revealing a Common Epithelial Inflammatory Response. Stem Cell Reports. 2021;16(4):940–953.

[470] Miller AJ, Dye BR, Ferrer-Torres D, et al. Generation of lung organoids from human pluripotent stem cells in vitro. Nat Protoc. 2019;14 (2):518–540.

[471] Vickovic S, Eralsan G, Salmen F, et al. High-definition spatial transcriptomics for in situ tissue profiling. Nat Methods. 2019;16(10):987–990.

[472] Stickels RR, Murray E, Kumar P, et al. Highly sensitive spatial transcriptomics at near-cellular resolution with Slide-seqV2. Nat Biotechnol. 2021;39 (3):313–319.

[473] Baccin C, Al-Sabah J, Velten L, et al. Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization. Nat Cell Biol. 2020;22(1):38–48.

[474] Van Den Brink SC, Alemany A, Van Batenburg V, et al. Single-cell and spatial transcriptomics reveal somitogenesis in gastruloids. Nature. 2020;582 (7812):405–409.

[475] Khan MM, Ernst O, Manes NP, et al. Multi-Omics Strategies Uncover Host–Pathogen Interactions. ACS Infect Dis. 2019;5(4):493–505.

[476] Zhou W, Sailani MR, Contrepois K, et al. Longitudinal multi-omics of host–microbe dynamics in prediabetes. Nature. 2019;569(7758):663–671.

[477] DiGiandomenico A, Keller AE, Gao C, et al. A multifunctional bispecific antibody protects against *Pseudomonas aeruginosa*. Sci Transl Med. 2014;6 (262):262ra155–262ra155. 262ra155.

[478] Patel A, DiGiandomenico A, Keller AE, et al. An engineered bispecific DNA-encoded IgG antibody protects against *Pseudomonas aeruginosa* in a pneumonia challenge model. Nat Commun. 2017;8(1):637.